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THE ROLE OF HSP90 IN PC-12 CELL SURVIVAL 
Christina Blume Clark 
December 5,2008 
The chaperone heat shock protein 90 (Hsp90) regulates physiologically and 
pathological cellular processes, by binding and stabilizing kinases involved in basal 
cellular functions and in cellular responses to stress, respectively. I hypothesize that 
Hsp90 binding to kinases Akt and Raf-l and to co-chaperone Cdc37 and Akt-dependent 
phosphorylation of Hsp90 regulate PC-12 cell survival. 
Hsp90 binding was inhibited using the classical Hsp90 inhibitor, Geldanamycin 
(GA). Disruption of Hsp90 binding by GA correlated with similar cell death at normoxia 
(RA) and at 0.1 % O2 sustained hypoxia (SH), suggesting that Hsp90 binding plays a role 
in cell survival. 
Indeed, GA cytotoxicity is attributed to disruption of Hsp90 binding, although the 
role of this drug's benzoquinone in its cytotoxicity was never studied. This study used 
GA, the antioxidant precursor N-acetyl cysteine (NAC), and the classical quinone 
menadione (MEN), to shows that oxidative stress and disruption of Hsp90 binding 
contribute to GA cytotoxicity. In addition, Hsp90 binding promotes survival by 
regulating protein degradation. Proteasomal inhibition prevented MEN-induced protein 
degradation, but failed to inhibit GA-induced protein degradation. Thus, GA induces 
v 
cytotoxicity by early disruption of Hsp90 binding, followed by oxidative stress~induced 
non~proteasomal protein degradation. 
Additional factors, such as Akt~dependent phosphorylation of Hsp90, may 
promote survival by regulating Hsp90 binding. Akt phosphorylates Hsp90 in vitro and in 
PC~12 cells expressing active Akt or exposed to 6h SH, concomitant with increased Akt 
phosphorylation. Proteomic analysis of Hsp90 immunoprecipitates identified additional 
Hsp90~binding proteins that may be recruited to and released from the Hsp90 complex in 
response to 6h SH. Most identified Hsp90 binding proteins dissociate in response to Akt 
inhibition by the Akt inhibitor, Akti 112, suggesting that Akt phosphorylation regulates the 
protein associations of the Hsp90 complexes. Survival studies with Akti 112 demonstrate 
that basal Akt phosphorylation, but not the 6h SH~induced increase in Akt 
phosphorylation is critical to survival. However, constitutive Akt phosphorylation is not 
sufficient to prevent death at 24h SH, suggesting additional factors are required for 
survival to SH. 
In summary, Akt~dependent phosphorylation of Hsp90 regulates protein binding 
and PC~ 12 cell survival. 
VI 
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CHAPTER I: INTRODUCTION 
Hypoxia: Definition, diseases, and overview of hypoxia-induced signaling pathways 
Hypoxia is defined as limited oxygen supply to cells that interferes with cellular 
processes. Hypoxia is associated with a variety of pathological conditions, such as 
ischemic diseases, sleep apnea, cardiovascular and pulmonary diseases, or stroke, and 
also occurs in the center of cancerous tumors [1-3]. Acute hypoxia induces a stress 
response, that upregulates heat shock proteins and activates survival kinases, Akt and 
Raf-l [4-8]. The growth factor-mediated PI3K1Akt pathway is implicated in the survival 
of neuronal cells to hypoxia and to a variety of injuries [9, 10]. The Raf-IIMEKIERK 
pathway is another survival pathway induced by hypoxia and other stressful conditions 
[6, 7, 11]. 
The PC-12 cell line is an established model for studying hypoxia-induced signaling 
The oxygen sensing neuroendocrine rat pheochromocytoma PC-12 cell line is a 
model widely used to investigate these molecular responses to hypoxia [6]. PC-12 cells 
are similar to neuronal-like carotid body type I cells that sense hypoxia and hypercapnia 
and playa role in the cardiovascular responses to oxygen deprivation, by transmitting this 
sensory information to the petrosal nerve [6]. In response to hypoxia, PC-12 cells and 
carotid body type I cells activate kinase signaling pathways, release catecholeminergic 
neurotransmitters [12-15], and depolarize by inhibiting 02-sensitive outward K+ currents 
[6, 16-19]. Compared to primary neurons, PC-12 cells are easier to culture, 
transform, and transfect. Therefore, this study used PC-12 cells to study cellular 
responses to 0.1 % 02 sustained hypoxia (SH). 
The heat shock protein family 
Primary responses to cellular stress involve the induction of heat shock proteins 
(Hsps). Hsps were first described as a family of proteins induced by and that protect cells 
from hyperthermia. Hsps are conserved chaperones that fold and stabilize proteins, refold 
misfolded proteins, and direct the elimination of irreversibly damaged proteins (Figure I) 
[20-25]. In addition, Hsp function is critical to the subcellular targeting of newly 
synthesized proteins [20]. Hsps regulate proliferation, cell cycle, and pro- and anti-
apoptotic pathways, and are implicated in multiple pathologies (Figure 1) [21-25]. 
Recently, some Hsps have been shown to also protect cells against hypoxia and other 
adverse conditions. Induction of inducible Hsp70 in response to anoxia [5], hypoxia [26], 
and ischemia [27] has been widely studied. Hsp70 has been implicated in hypoxic [28] 
and ischemic pre-conditioning[29, 30], and protects the brain from ischemia [31-33]. 
Additional Hsps, such as Hsp27 and Hsp90 have been implicated in the cellular response 
to hypoxia [34-37]. 
Introduction to the chaperone Hsp90 
Hsp90 regulates a broad spectrum of biological processes, by interacting with and 
stabilizing a wide variety of "client proteins," including several kinases, co-chaperones, 
transcription factors, receptors, Hsps, and other binding proteins (Figure 2) [38, 39]. The 
chaperone Hsp90 is one of the most abundant cytosolic Hsps [40,41], and is primarily 
localized to the cytosol in unstressed cells. However, low levels of Hsp90 are known to 
be located in other subcellular compartments, including the plasma membrane, nucleus 
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Figure 1. The functions of heat shock proteins. In unstressed cells, heat shock proteins 
fold proteins during protein synthesis. In stressed cells, expression of heat shock proteins 
is increased by denatured proteins, and heat shock proteins help repair and eliminate 
damaged proteins. By interacting with damaged proteins, heat shock proteins can direct 
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Figure 2. Heat shock protein 90 regulates a variety of cellular pathways and processes by 
binding to clients proteins and co-chaperones. 
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and mitochondria in rat oligodendrocyte precursors derived from embryonic cerebral 
hemispheres [42]. Hsp90 may also be located in the perinuclear endoplasmic reticulum 
[43]. In addition, Hsp90 is located at the cytoskeleton, where it may maintain cytoskeletal 
architecture [44, 45]. Upon stress, Hsp90 translocates from the cytosol to the nucleus [46, 
47], and may also translocate from the cytoplasm to the cytoskeletal membrane in human 
platelets during platelet adhesion to collagen [48]. Thus, Hsp90 may shuttle its binding 
proteins to numerous subcellular locations in response to stress. 
Two constitutive isoforms of Hsp90 exist, the more inducible Hsp90a and the less 
inducible Hsp90~. In cells, Hsp90a and Hsp90~ monomers, homodimers, and 
heterodimers occur in an equilibrium that may be shifted in response to stressful 
conditions, including hypoxia and cancer [49]. 
Each Hsp90 molecule has ATPase activity and carries two ATP-binding sites and 
multiple client protein and co-chaperone binding sites (Figure 3) [38]. The N-terminal 
ATPase domain of Hsp90 harbors an A TP/ ADP-binding site, that can bind to one 
molecule of ATP, ADP, GTP, or CTP [50, 51], or to the competitive Hsp90 inhibitors, 
Geldanamycin (GA) and Deguelin [52, 53]. The C-terminal ATP binding site of Hsp90 
[50] (amino acids 657-677) binds to the Hsp90 inhibitor Novobiocin, which also 
allosterically inhibits the N-terminal ATP-binding site [52, 54, 55]. In addition, the C-
terminal A TP binding site of Hsp90 is close to the binding site of Cisplatin, another 
Hsp90 inhibitor [52, 56, 57]. 
The ATP-dependent chaperone cycle of Hsp90 
The ATP-dependent chaperone cycle of Hsp90 regulates the binding of Hsp90 to 
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Figure 4. GA inhibits the A TP-dependent chaperone cycle of Hsp90. Dimeric open 
conformation Hsp90 binds to co-chaperones and client binding proteins. The Hsp90 
complex then binds to ATP, causing Hsp90 to switch to a closed conformation that 
tightly holds on to co-chaperones and clients, allowing clients to mature and or become 
more stable. Clients and co-chaperones then dissociate from Hsp90 during ATP 
hydrolysis. GA inhibits the Hsp90 chaperone cycle by competing with A TP for binding 
to Hsp90, stalling co-chaperone- and client-bound Hsp90 in an open conformation, in 
which co-chaperones and incompletely processed clients are prone to dissociate. 
Immature and unstable clients released by Hsp90 are targeted for ubiquitination and 
degradation more so than mature stabilized clients. However, the quinone group of GA 
may induce oxidative stress, that mayor may not modify the Hsp90 complex by 
oxidizing proteins. 
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of ATP to the N-terminal ATP-binding domain alters the conformation of the Hsp90 
dimers, allowing proteins to bind to or dissociate from the Hsp90 complex (Figure 4). 
Upon ATP hydrolysis, opening of the Hsp90 dimer allows the release of fully processed 
proteins, that are relatively resistant to ubiquitination and proteasomal degradation 
(Figure 4). GA, Deguelin, and Novobiocin, which inhibit the N-terminal A TP-binding 
site, decrease the expression of kinases and other Hsp90-binding proteins [51, 53, 54, 56, 
59]. In contrast, the C-terminal A TP binding site of Hsp90 plays a role in the interactions 
of Hsp90 with steroid receptors. Cisplatin, which targets this later region of Hsp90, 
affects the expression of steroid receptors, without altering the expression of kinases in 
neuroblastoma cells [51,54,56,59]. In summary, ATP binding and hydrolysis regulate 
the binding of kinases, steroid receptors, and other proteins to Hsp90. 
The Hsp90 inhibitor Geldanamycin 
SiRNA silencing of Hsp90 is rarely used to study Hsp90 because the high 
expression of Hsp90 in cancer cells makes siRNA silencing of this chaperone 
challenging. Thus, GA has been extensively used to study the chaperone function of 
Hsp90. GA inhibits the chaperone function of Hsp90, by competing with A TP for 
binding to the N -terminal A TP-binding pocket of Hsp90 (Figure 4). GA binding disrupts 
the ATP cycle by locking the Hsp90 dimer in an "open" clamp conformation (Figure 4) 
[41,60], that causes premature dissociation of incompletely processed client proteins. 
These incompletely processed proteins are prone to ubiquitination and 
degradation, and their expression is consequently decreased. Decreased expression of 
pro-survival proteins may decrease cell survival, suggesting an important role for Hsp90 
binding in regulating cell survival by regulating protein stabilities. Indeed, GA 
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cytotoxicity is widely attributed to disruption of Hsp90 binding. Indeed, GA and its 
derivatives have been shown to disrupt cell cycle and induce apoptosis with significant 
decreases in Akt and ERK expression, in many cancer cells [61,62]. 
GA decreases the expression of many Hsp90-binding proteins be increasing their 
proteasomal degradation, suggesting Hsp90 protects its binding proteins from 
proteasomal degradation. GA-induced disruption of Akt binding to Hsp90 was shown to 
decrease Akt expression by targeting Akt to proteasomal degradation [63]. In addition, 
GA induces proteasomal degradation of Raf-l [64] and other kinases, including the 
mitogen-activated protein (MAP) kinase superfamily member, MOK [65]. GA also 
induces internalization of the Hsp90-binding kinase ErbB2, by a proteasome dependent 
pathway, that proceeds ErbB2 degradation by the lysosomes [66]. 
In addition, Finn et. al. propose a role for Hsp90 in negatively regulating 
chaperone mediated autophagy (CMA), a selective process that targets specific cytosolic 
proteins for lysosomal degradation [67]. Hsp90 inhibition by GA was shown to globally 
increase CMA [67], and Hsp90 may regulate the CMA of Hsp90-binding NFkB pathway 
kinases, NIK and IKK [68, 69]. However, oxidative stress may induce CMA of oxidized 
proteins [70], and the role of GA-induced oxidative stress in CMA was not examined in 
these studies. In the absence of GA, Hsp90 binding may facilitate refolding of oxidized 
cytosolic proteins, preventing their translocation to lysosomes, that only accept unfolded 
proteins [67]. Regulation of CMA by Hsp90 may playa role in cellular survival. Indeed, 
alterations in CMA have been shown in models of normal aging and the age-related 
neurodegenerative diseases, Alzheimer's Disease and Parkinson's Disease [71]. 
9 
GA and other ansamycin class inhibitors appear to preferentially target the Hsp90 
complexes of cancer cells [72]. Therefore, several GA derivatives were moved to clinical 
trials to be combined with conventional chemotherapy [73-76]. However, GA and its less 
toxic derivatives are also toxic to normal cells, limiting the doses and durations of 
treatment that can be used [77]. While higher doses of GA display significant 
cytotoxicity, low doses of GA and of its derivatives are neuroprotective in P-19 neuronal 
cultures against antineoplastic drugs toxicity [78] and against dopamine toxicity in a 
mouse model of Parkinson disease [79]. This neuroprotective effect is believed to result 
from GA induction of Hsps, that is mediated by heat shock factor (HSF) release from 
Hsp90 binding and increased transcription of Hsp70 [79]. Therefore, the pro-survival 
effects of GA appear related to the release and induction of pro-survival proteins at lower 
doses, while this effect is unable to compensate for disruption of critical survival 
pathways at higher doses. 
Disruption of Hsp90 binding may not be the only contribution of GA to 
cytotoxicity. GA carries a reactive benzoquinone moiety that generates reactive oxygen 
species (ROS) [80, 81]. ROS are produced by molecular oxygen-dependent redox-cycling 
of the drug's reactive quinone, during which the quinone is converted to a semiquinone 
via one-electron reduction by NADPH-dependent reductase enzymes [81]. Semiquinones 
undergo a one electron oxidation reaction with molecular oxygen that produces a 
cytotoxic superoxide radical and converts the semiquinone back into a quinone [82]. 
Thus, quinones may repeatedly redox-cycle, and superoxide products may produce 
additional ROS by interacting with proteins, lipids, and nucleic acids. This oxidative 
stress generated by GA may lead to cellular stress and demise via oxidation and 
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degradation of proteins. However, the potential role of the GA benzoquinone group in 
GA cytotoxicity and disruption of Hsp90 binding has not been examined. 
Therefore, to examine the relative contributions of oxidative stress and of 
disruption of Hsp90 binding to GA cytotoxicity, the classical quinone menadione (MEN) 
was used as a positive control for non-specific quinone-induced oxidative and arylation 
stress in cells. MEN is similar to GA in that both compounds have anticancer effects and 
each harbors one reactive quinone group, that produces ROS in cells, decreases NADPH, 
and non-enzymatically forms covalent conjugates with glutathione cysteine residues 
(Figure 5) [83-85]. In addition to using MEN, this study also assessed the effect of an 
antioxidant precursor on the outcomes of GA treatment. GA oxidative properties are 
related to its semiquinone cycling, which may deplete cells of NADPH required as a 
cofactor for gluthathione redox cycling. Therefore, the antioxidant precursor N-acteyl 
cysteine (NAC) was selected because it reduces ROS by providing cellular reduced 
glutathione in an NADPH-independent manner. In addition, Fukuyo et. al. recently 
examined the role of oxidative stress in decreased expression and activity of the kinase B-
Raf induced by the GA analog, 17-demethoxygeldanamycin (17-DMAG) [86]. 
Hsp90 binding regulates cell survival 
Hsp90 regulates cell survival by stabilizing its binding proteins. Indeed, 
disruption of Hsp90 binding increases client protein degradation [39, 87-89]. Hsp90 
binds to Hsp70, and thereby regulates the stress responses and inductions of Hsp70 and 
of other heat shock proteins, by regulating the activity of heat shock factor (HSF) [90, 
91]. In addition, Hsp90 also binds pro-apototic mitochondrial proteins released into the 







Figure 5. The classical quinone MEN is similar to GA. Both compounds harbor one 
reactive quinone group, that produces ROS in cells, decreases NADPH, and 
non-enzymatically forms covalent conjugates with glutathione. 
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thereby stabilizes the survival kinases Akt and Raf-l and binds to their co-chaperone, 
Cdc37 [39,64,92-97]. Disruption of Akt binding to Hsp90 by Hsp90 inhibitors leads to 
Akt degradation and cell death [63]. Hsp90 binds to and regulates the folding of multiple 
additional proteins, among them many cell cycle regulating proteins and proteins 
associated with cancer [39, 98]. In cancer cells, the expression of Hsp90 and of its 
binding proteins is upregulated. Thus, several inhibitors of Hsp90 binding, currently in 
clinical cancer trials, may induce cell death and disrupt the cell cycle, by decreasing the 
expression of and activity of Hsp90 and Hsp90-binding proteins, including survival 
kinases, transcription factors, and steroid hormone receptors [59,99-105]. Although 
Hsp90 acts as an anti-apoptotic factor by sequestering pro-apoptotic proteins and by 
activating anti-apoptotic proteins, Hsp90 has also been shown to promote apoptosis by 
associating with a cyclin-dependent kinase [106-108]. The balance between Hsp90 
interactions with these pro- and anti-apoptotic pathways determines cellular fate. 
Hsp90 binding to Akt and Raf-l may playa role in cell survival because these 
kinases are involved in survival signaling responses. Both the PI3K (phosphoinositide 3-
kinase)/Akt and the Ras/Raf (Ras-activated factor)/MAPK (mitogen-activated protein 
kinase) pathways have been implicated in cell survival and regulation of apoptosis [6, 
109-111]. 
The growth factor-mediated PI3K1Akt pathway is implicated in neuronal cells 
survival to hypoxia and to a variety of injuries [9, 10]. In addition, Akt is implicated in 
three hallmarks of cancer: self-sufficiency in growth signals, evasion of apoptosis, and 
sustained angiogenesis [52]. Akt prevents cell death by interacting with several signaling 
pathways. Akt plays roles in NFKB-induced transcription of anti-apoptotic genes, and in 
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regulating forkhead pathways, that induce transcription of pro-apoptotic genes [6]. In 
addition, Akt phosphorylates Bad, which reduces pro-apoptotic mitochondrial 
cytochrome c release, cytosolic apoptosome assembly, and the caspase cascade [6, 112]. 
Furthermore, Akt has been shown to directly inhibit activation of caspase 9 in vitro [6]. 
Hsp90 binding to kinases 
Hsp90 binds to the kinase domains of its kinase binding proteins, and this docking 
of Hsp90 onto kinase domains may protect kinases from dephosphorylation by 
phosphatases and from proteosomal degradation, and may also regulate the onset of 
kinase activation [38, 113, 114]. Hsp90 binding to PDKI promotes stabilization and 
signaling of PDKI by preventing the proteosomal degradation of PDK1 [115]. In 
addition, Hsp90 binding also prevents proteasome-dependent degradation of Integrin-
linked kinase (ILK), another upstream kinase that phosphorylates Akt [113]. Hsp90 
binding to the tyrosine kinase pp60v-src stabilizes this kinase and lowers its tyrosine kinase 
activity [116]. While bound to Hsp90, cytosolic pp60v-src is unphosphorylated and 
inactive, whereas dissociated and plasma membrane bound pp60v-src has active tyrosine 
kinase activity [116]. 
Hsp90 binding to Akt is essential for Akt phosphorylation and protects Akt from 
dephosphorylation by protein phosphatase 2A (PP2A) and from degradation (Figure 6) 
[63, 114]. In addition, Akt needs Hsp90 for its conformational maturation [52, 114]. 
Deletion mutagenesis studies identified an Akt binding site on Hsp90a (amino acids 335 
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Figure 6. Akt is regulated by binding to Hsp90 and Cdc37 and by dephosphorylation and 
phosphorylation. 
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- 309) was shown to bind to Hsp90 (Figure 7) [114]. Although Akt is phosphorylated 
when bound to Hsp90, phosphorylation of Akt is not a requirement for Akt binding to 
Hsp90 [114]. Several studies report that Akt binding to Hsp90 is required for Akt 
stability and for its activation in human and mouse cancer cell lines and in BALB/3T3 
and human 293T cells, stabilizing phospho-Akt levels and Akt kinase activity [63, 113, 
114]. However, in vitro studies showed no Hsp90 effect on Akt kinase activity [63, 113, 
114]. This suggests that Hsp90 is not the only determinate of Akt activity, and additional 
proteins may regulate Akt activity. 
Since the Akt kinases PDK1 and ILK also bind to Hsp90, Hsp90 may serve as a 
scaffold protein [63], bringing PDK1 and ILK close to Akt to allow for Akt activation by 
these upstream kinases (Figure 6). Akt-Hsp90 complexes, PDK1-Hsp90 complexes, and 
Akt-PDK1 complexes have been shown in several cell types by immunoprecipitation 
studies [63, 114, 115, 117, 118]. In addition, Akt-Hsp90 binding requires additional co-
chaperone proteins, and the stoichiometry and regulation of Akt-Hsp90 binding by these 
co-chaperones is unclear [21]. 
Hsp90 also modulates the Raf/MEKIERK kinase survival pathway by binding to 
the upstream kinase Raf-l and to Cdc37, a co-chaperone that regulates Akt and Raf-l 
[96, 119]. The Cdc37 amino acid region 181 - 200 binds to Raf-l and is within the 
Hsp90-binding domain, located near the Akt binding domain [120-122]. Thus, Cdc37 and 
Hsp90 are scaffold proteins that may facilitate crosstalk between the Akt and Raf-l 
signaling pathways [123-128]. Cdc37 is critical for Hsp90 binding to kinases [120, 121], 
and the ternary Raf-1-Cdc37-Hsp90 complex is essential to Raf-1 activity in Sf9 cells and 








Figure 7. The stability and activity of Akt is positively regulated by binding of the Akt 
kinase domain to Hsp90. 
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Role of Hsp90 in cell survival responses to hypoxia 
By interacting with its binding proteins, Hsp90 may playa general role in survival 
and or a role in survival to hypoxia and to other stressors following hypoxic exposure. 
Recently, Hsp90 was shown to playa role in hypoxic pre-conditioning induced protection 
of cardiomyocytes [36]. Chiosis et. ai. first hypothesized that stressful conditions 
including hypoxia and cancer may increase the binding of proteins to the Hsp90 complex 
[49]. The protein interactions of these multi-protein Hsp90 complexes that may form in 
response to hypoxia may play roles in cellular responses to hypoxia. Indeed, recently 
Hsp90 has also been shown to stabilize the survival kinase Integrin-linked kinase (ILK) 
in hypoxic endothelial cells [129], and Hsp90 and Cdc37 binding to and stabilization of 
ILK has been demonstrated previously in normoxic cells [113]. Integrin-linked kinase 
(ILK), a serine/threonine kinase involved in cell adhesion, proliferation, and cell survival, 
interacts with beta-integrins and growth factor receptors in response to extracellular 
signals [113]. In response to hypoxia, ILK protein levels and kinase activity increase and 
ILK phosphorylates survival kinases Akt and ERK, resulting in vasculogenesis and 
hypoxia inducible factor I a (Hif-l a) signaling [129]. In addition, Hsp90 binds to and 
regulates Hif-1a [130], a transcription factor that regulates hypoxia-induced apoptosis 
[131], metabolic adaptation of cells to hypoxia [132], and hypoxic tumor cell growth and 
invasion [133]. Hsp90 binding to Hif-1 a positively regulates the Hif-1 a signaling 
pathway by stabilizing Hif-1a [134, 135], and playing roles in hypoxia-induced 
activation of [136] and DNA binding of Hif-1a [137], and transcription of vascular 
endothelial growth factor (VEGF) [138]. In addition to stabilizing HIF-la, Hsp90 
increases phosphorylation of the pro-survival transcription factor CREB [136]. Hsp90 
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also positively regulates the hypoxia-induced signaling pathway of c-Jun / activator-
protein 1 (AP-l), that upregulates transcription of protective genes in colon 
adenocarcinoma cells [137]. Furthermore, in a model of myocardial ischemia, Hsp90 
binds to eNOS, thereby facilitating eNOS phosphorylation by Akt and increasing 
resistance to myocardial ischemia [37, 139]. In conclusion, previous studies by others 
suggest that the protein interactions of Hsp90 may playa role in cellular responses to 
hypoxia. 
Regulation of the Hsp90 complex by phosphorylation 
In response to hypoxia, Akt phosphorylation increases in PC-12 cells. Whether 
Akt phosphorylation affects the formation of Hsp90 complexes in response to hypoxia is 
currently unknown. Phosphorylation of Hsp90 and of its binding proteins by kinases may 
regulate the binding of proteins to the Hsp90 complex. Hsp90 and the Hsp90-binding 
proteins Raf-l and Hsp70 are known substrates of Akt, and Hsp90 and Cdc37 have 
putative Akt phosphorylation sites [140-142]. 
The phosphorylation state of Hsp90 complexes may regulate Hsp90 binding. 
Hsp90 is phosphorylated by Akt as well as several other kinases [143] (PKA, CKII, 
GSK3-a, AK), and several phosphorylated forms of Hsp90 have been identified [144]. 
Tyrosine phosphorylation of Hsp90 has been shown at the plasma membrane, but not in 
the cytosol of HEK293 cells, associating with and regulating P2X7 receptor function 
[145] and in HUVEC cells, associated with VEGF receptor [146]. Futhermore, Hsp90 
autophosphorylates in yeast, E.coli, Brassica napus, rat, and pig [143,147-149], and 
phosphorylates histones and casein in Brassica napus [149]. Autophosphorylation of 
Hsp90 is not altered by GA in porcine testis [143]. However, phosphatase associations 
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and dissociations from Hsp90 complexes may influence phosphorylation of Hsp90 and 
Hsp90-bound kinases, thereby regulating kinase-Hsp90 interactions. Dissociation of 
protein phosphatase 1 (PP1) from Hsc70/Hsp90/PPI complexes results in 
dephosphorylation of Hsc70 and dissociation of Hsp90 from Hsc70 [48]. 
Hsp90 binding is also regulated by phosphorylation of the binding protein Cdc37. 
Phosphorylation of Cdc37 at Ser13 by Casein kinase II positively regulates Cdc37 
binding to Hsp90 and to Akt and Raf-l, and stabilizes and activates Hsp90-dependent 
kinases in rabbit reticulocyte lysates and in COS7 cells [121, 150, 151]. Furthermore, 
Cdc37 phosphorylation by CK II in yeast positively regulates the signaling pathways of 
multiple GA-sensitive Cdc37- and Hsp90-binding kinases by activating Cdc37 in a 
positive feedback loop [152]. In addition, dephosphorylation of Hsp90-bound Cdc37 at 
Ser 13 by overexpression of protein phosphatase 5 (PP5/Ppt 1) decreases expression of C-
Raf and phosphorylation of ERKl/2 in the human colon carcinoma cell line, HCT 116 
[153]. In summary, phosphorylation and dephosphorylation of Hsp90 complex proteins 
may alter the activity of and stability of Hsp90 binding proteins. 
Regulation of the Hsp90 complexes in diseases 
However, it is unclear how Akt phosphorylation and dephosphorylation and Akt-
dependent phosphorylation of Hsp90 and its co-chaperones may affect the protein 
interactions of Hsp90 complexes in normal cells and cancer cells [49]. Understanding the 
regulation of Hsp90 protein interactions by Akt at physiologic and pathological 
conditions may be important in the development of novel treatments for a variety of 
medical conditions. Indeed, Hsp90 inhibitors that disrupt the Hsp90 complex are in 
clinical trials for metastatic stages of melanoma and prostate cancers and multiple 
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myeloma [76, 154-159]. In addition, the Hsp90 inhibitor 17-(dimethylaminoethylamino)-
17-demethoxygeldanamycin (DMAG) has anti-tumor activity in animal models of breast, 
pancreatic, and small cell lung cancer [100, 102], and increases the sensitivity of 
lymphoma cells to doxorubicin chemotherapy [160]. Thus, it may be worthwhile to 
further develop Hsp90 inhibitors as adjuvants to conventional chemotherapies and 
radiotherapies, that hypoxic cancer cells often develop resistant against. Furthermore, 
studies with another GA analog, 17-allylamino-17-demethoxygeldanamycin (17-AAG), 
in a mouse model of spinal and bulbarmuscular atrophy (SBMA) suggest that Hsp90 
inhibitors may also be useful in the treatment of neurodegenerative diseases [161]. 
However, the regulation of normoxic and hypoxic Hsp90 complexes and their roles in 
neuronal and cancer cell survival, resistance to chemotherapies, vasculogenesis, cancer 
metastases, and wound healing remain under investigation [129,161,162]. 
Hypothesis 
Therefore, the central hypothesis of this study is that the Hsp90 signaling complex 
regulates PC-12 cell survival and is modulated by phosphorylation of Hsp90. 
Specific Aim 1 
In Specific Aim 1, Hsp90-binding proteins were identified in normoxic and 
hypoxic celllysates, and the roles of these proteins in cell survival were examined. 
Specific Aim 2 
The purpose of Specific Aim 2 was to determine whether Akt and Akt-dependent 
phosphorylation events regulate cell survival and protein binding to normoxic and 
hypoxic Hsp90 complexes. 
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CHAPTER II: MATERIAL AND METHODS 
General Experimental Approach 
The interactions between Hsp90 and its various binding proteins and their role in 
PC-12 cells survival to normoxia (RA) or sustained hypoxia (0.1 % O2 ; SH) were studied, 
using a custom-designed chamber maintained at an atmospheric oxygen level of 0.1 % 02. 
In Specific Aim I, proteomics strategies were implemented to identify critical signaling 
protein interactions with Hsp90 that mediate survival during normoxia and hypoxia 
(Figure 8). Protein-protein interactions were characterized using co-immunoprecipitation 
and mass spectrometry analysis of immunoprecipitates. In Specific Aim 2, the focus was 
on Akt-dependent regulation of Hsp90 binding in response to hypoxia (Figure 9). 
Materials 
All reagents were from Sigma (St Louis, MO) unless otherwise specified. Cell 
culture media and additives and materials for protein separation were from Invitrogen 
(Carlsbad, CA), unless otherwise specified. Trypan Blue (0.4%; J. T. Baker Chemical 
Company, Phillipsburg, NJ) and 3-(4, 5-methylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT; Calbiochem, San Diego, CA) were dissolved in phosphate buffered saline 
(PBS). Geldanamycin (GA; LC Laboratories, Inc., Woburn, MA), Menadione (MEN), 
MG-132 (Calbiochem), 2',T-dichlorofluorescin (DCF; Molecular Probes, Eugene, OR), 
Bafilomycin Al (BAF; Calbiochem), and Akti1/2 (Akt Inhibitor VIII; Calbiochem) were 
dissolved in sterile DMSO. N-acetyl cysteine (NAC) was dissolved in RPMIl640, to 
which 10% horse serum, 5% fetal bovine serum, and 1 % antibiotics/antimycotics was 
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Figure 8. Overview of methods for Specific Aim 1. 
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added following pH adjustment and filter sterilization. Protein A-conjugated Agarose 
beads and Fugene HD Transfection Reagent were from Roche Applied Science 
(Indianapolis, IN). Empty vector pUSE Amp DNA plasmids and wild type Akt (WT 
Akt)- and constitutively active myristoylated Akt (CA Akt)-encoding pUSE Amp DNA 
plasmids, protein phosphatase 2A (PP2A), and PP2A buffer were from MilliporelUpstate 
(Billerica, MA). Lab-Tek II Chamber Slides were from Nalge Nunc International 
(Rochester, NY) and DAPI (4', 6-diamidino-2-phenylindole dihydrochloride) was from 
Sigma. 
Cell culture 
Rat pheochromocytoma PC-12 cells (American Type Culture Collection, 
Manassas, VA), were cultured on rat tail collagen-coated plates in RPM II 640 medium 
supplemented with 10% horse serum, 5% fetal bovine serum, and 1% 
antibiotics/antimycotics, at 37°C in 5% CO2 incubators. Experiments were performed at 
similar starting cell confluence that was estimated by light microscopy and MTT assay. 
Pre-treatments of cells with or without MG-132 were initiated at 40% - 50% starting 
confluence. Cell exposures to NAC, MEN, GA, BAF, and Akti1l2 were initiated at 70%-
80% starting confluence. 
Exposures of cells to drugs 
To establish the dose-dependent time course of GA cytotoxicity, cells were 
treated for lh, 3h, 6h, 9h, 12h, or 24h with 10 or 20 f.lM GA or DMSO vehicle. For 
antioxidant studies, cells were pre-treated lh with I mM NAC or vehicle, followed by lh, 
6h, or 24h treatments with 20 f.lM MEN, 20 f.lM GA, or vehicle. To determine if Hsp90 
binding protects proteins from proteasomal degradation, cells were pre-treated for 21h 
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with DMSO or 150 nM MG-132, and treated for 1h with DMSO or 20 /-lM GA at 
normoxia, or treated with DMSO, 20 /-lM MEN, or 20 /-lM GA starting at 3h prior to 
exposures to 6h or 24h of normoxia or hypoxia. To determine if Hsp90 binding protects 
proteins from lysosomal degradation, cells were pre-treated 30 min with DMSO or up to 
750 nM Bafilomycin Al (BAF), and treated with DMSO, 20 /-lM MEN, or 20 /-lM GA for 
6h at RA. To determine if phosphorylation of Akt regulates cell survival to hypoxia by 
regulating Hsp90 complexes, cells were pre-treated with DMSO vehicle or 1 /-lM or 
20 /-lM Akti1l2 for 3h, prior to exposures to normoxia or hypoxia. 
Exposures of cells to hypoxia 
PC-12 cells were exposed to 6h or 24h of normoxia (RA; 21 % O2, 5 % CO2) or to 
sustained hypoxia (SH; 0.1 % O2, 5% CO2, and balanced N2), using computer-controlled 
incubation chambers linked to an external 02-C02 computer-driven controller 
(Biospherix, Redfield, NY). Chamber O2, N2, and CO2 gas levels were continuously 
monitored, recorded, and adjusted according to the desired programmed profile, using an 
AD-controller interface and software (Biospherix). 
Transfections 
Cells 60 - 70% confluent were transfected in serum free medium with Fugene HD 
Transfection Reagent pre-incubated with 2/-lg of DNA plasmids and RPMIl640 medium 
for 15 min at room temperature. Cells were transfected with either empty vector plasmids 
or c-Myc tagged wild type Akt (WT Akt)- or constitutively active Akt (CA Akt)-
encoding plasmids. Transfected cells were incubated at 3rC for 5 hrs. Serum 
concentrations were restored prior to overnight incubation. At 24h post-transfection, cells 
were exposed to 24h of RA or SH. Transfection experiments were repeated twice. 
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Cell viability 
Viability was measured by MTT or Trypan blue exclusion assays. MTT assay was 
performed by adding the formazan dye MTT (3-(4, 5-methylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) to cells at Ih before collection. Cell pellets were washed 
with PBS to remove excess MTT, and the reduced formazan products were solubilized with 
DMSO. Optical density was measured at 450 nm by an Original Multiskan EX plate reader 
(Thermo Electron Corporation). Trypan blue exclusion assay was performed by counting 
Trypan blue stained cells on a hemacytometer, using a light microscope connected to a 
digital camera and computer with Motic imaging software. Cells that did not absorb blue 
dye were counted as live cells. 
Reactive oxygen species (ROS) production 
Ih prior to collection, 5 ~M DCF was added to cells. Cells were centrifuged, 
resuspended in PBS, and transferred to black 96-well plates (Greiner Bio-One, Monroe, 
NC). Fluorescence kinetics was measured for 60 min at 485 nm excitation and 535 nm 
emission wavelengths using a fluorescent microplate reader (TECAN SPECTRAFLUOR 
Plus). 
In vitro kinase assays 
Recombinant human active Akt (400 ng), 1 flg recombinant human 
Hsp90a (Stressgen, Victoria, BC, Canada) or Hsp90p (Medical and Biological 
Laboratories, Woburn, MA) and 10 J1Ci [y_32p]ATP in 30 flL of kinase buffer (20 mM 
HEPES, 10 mM MgCI2, 10 mM MnCh) were incubated for 45 min at 25°C, in the 
presence or absence of Aktide-2T (200 ~M) or scrambled peptide (200 ~M), separated by 
SDS-PAGE and revealed by autoradiography [140]. 
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PP2A treatment of lysates 
Prior to 2-D SDS PAGE separation, lysates were treated with or without 0.5 units 
of protein phosphatase 2A for 1.5 h at 30°C in PP2A buffer. Samples were then processed 
as described below for 2D gel electrophoresis. 
Antibodies 
Primary antibodies used for immunoblotting were purchased from Santa Cruz 
(Santa Cruz, CA; Akt, phospho-Ser 473 Akt, ERK1, Cdc37, Raf-I, SOD-I), anti-
phospho-Ser473 Akt, Akt, and anti-Myc-Tag (9B11) were from Cell Signaling 
Technology (Danvers, MA), anti-Hsp90a/~ was from Assay Designs/Stressgen (Ann 
Arbor, MI), and anti-ubiquitin and anti-~-actin were from Sigma. Secondary antibodies 
were anti-rat IgG HRP from Assay Designs, anti-rabbit HRP from Cell Signaling 
Technology, and goat anti-mouse IgG HRP, Exacta Cruz anti-mouse and anti-rabbit 
HRP-conjugates were from Santa Cruz. For immunoprecipitations, Hsp90a/~ antibody 
was from Santa Cruz and anti-Akt (Catalog No. 9272) was from Cell Signaling 
Technology. For immunostaining, the primary antibodies rabbit anti-Akt1l2, rabbit anti-
GRIPI, mouse anti- Hsp90a/~ (F-8), and normal mouse and rabbit IgG isotype controls 
were from Santa Cruz, and the secondary fluorochrome antibodies (Jackson 
Immunoresearch Laboratories, West Grove, PA) were donkey anti-rabbit TRITC (with 
rhodamine red fluorescence) and donkey anti-mouse FITC (with green fluorescence). 
Collection of cells 
Cells were detached by pipetting up and down and collected by centrifugation at 
900 rpm for 4 min at 4°C. Pellets were washed with PBS and centrifuged at 4,000 rpm for 
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5 min at 4°C, and supernatant was aspirated. Pellets were stored at -80°C prior to use, or 
were immediately resuspended in lysis buffer. 
Preparation of celllysates 
Celllysates (NP-40 soluble lysates fractions) were prepared by resuspending 
pellets in lysis buffer (0.4% NP-40, 1 % glycerol, 50 mM tris at pH 7.5, 1 mM Na 
orthovanadate, 150 mM NaCl, 10 mM EDTA, 100 mM NaF, 20 mg/mL leupeptin, 
10 mg/mL aprotinin, 0.5 mM PMSF). Resuspended cells were incubated on ice for 
10 min, and then sonicated using a Fischer Scientific Sonic Dismembrator 60 set at 3 (5X 
for 1 sec, IX for 5 sec, and again 5X for Isec), and centrifuged at 4°C at 14,000 rpm 
(18,000 rcf) for 15 min. Total protein concentrations were determined in the supernatant 
by DC Bio-Rad protein assay (Bio-Rad, Hercules, CA). 
Immunoprecipitation 
Lysates were incubated with Protein A-conjugated Agarose beads (Roche) and 
either primary immune antibody or non-immune isotype control antibody in lysis buffer 
with 0.4% NP-40. Immunoprecipitates were washed in lysis buffer without NP-40. For 
Hsp90 immunoprecipitations, mouse monoclonal IgG2a anti-Hsp90aJ~ (F-8) antibody 
(Santa Cruz) was used, and normal mouse IgG antibody (Santa Cruz) served as an 
isotype control. Compared to four other anti-Hsp90 antibodies tested, this anti-Hsp90 
antibody immunoprecipitated the highest quantities of Hsp90 and co-immunoprecipitated 
the highest quantities of the kinase co-chaperone Cdc37 (data not shown). Therefore, the 
above anti-Hsp90 antibody was selected to study Hsp90 interactions with hypoxia-
inducible kinases. Protein A beads were selected over protein G and protein A/G beads 
for their lesser non-specific protein binding. 
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Immunoblotting 
Lysate fractions were separated by SOS PAGE using 4 - 12% tris-glycine gels for 
I-dimensional (1-0) gel immunoblotting, or by 2-dimensional SOS PAGE, using 
non-linear pH 3 -10 ZOOM immobilized pH gradient (IPG) strips rehydrated overnight 
with lysates in urea/thiourea solubilization/rehydration buffer (Proteomic Research 
Services, Inc.). IPG strips were washed with Equilibration buffers 1 and 2 (Proteomic 
Research Services, Inc.). Proteins were separated by isoelectric focusing (IEF) using a 
ZOOM IPG Runner Mini-Cell connected to a Thermo Electron 6000P Power Supply, set 
at a step voltage program (200V for 20 min, 450V for 15 min, 750V for 15 min, and 
2000V for 105 min). Following IEF, proteins in IPG strips were separated by molecular 
weight. IPG strips were applied to I mm wide NuPAGE Novex 4 - 12% Bis-Tris ZOOM 
gels, and gels were run at 200V for Ih in IX NuPAGE MOPS SOS Running Buffer with 
NuPAGE antioxidant. Proteins separated by 1-0 and by 2-0 SOS PAGE were transferred 
onto nitrocellulose membranes and immunoblotted. Transfer efficiency and protein 
loading were verified by Ponceau-S staining of the membranes. Proteins were detected by 
overnight incubation with primary antibody and visualized using horseradish peroxidase-
conjugated secondary IgG antibodies and the enhanced chemiluminescence reagent 
ECL-Plus (General Electric, Niskayuna, NY). Immunoblots of lysates and of 
immunoprecipitates were repeated three or more times. 
Densitometry analysis of immunoblots 
Protein bands on films of immunoblotted immunoprecipitates were quantified by 
densitometry analysis, using Adobe Photoshop CS2 Version 9.0.2. Protein bands were 
30 
selected with the lasso tool. The mean luminescence and pixel sizes of selected areas 
were used to calculate the densitometry units (Y DU) of each protein band. 
Equation for calculating Y DU of a protein: 
Y DU Protein = Pixels x (255 ~ Mean Luminescence) 
The densitometry units of co-immunoprecipitated proteins were normalized by dividing 
these values by the densitometry units of the immunoprecipitated proteins. The binding 
of co-immunoprecipitated proteins to the immunoprecipitated protein in inhibitor-treated 
or SH samples was compared to that of vehicle-treated or RA samples, by expressing the 
normalized protein densitometry units of the inhibitor-treated or SH sample as a 
percentage of the normalized protein densitometry units of the vehicle or RA 
immunoprecipitates. 
Equation for calculating % of binding relative to vehicle: 
% = 100 x (Y DU Co-IP protein in inhibitor sample / Y DU IP protein in inhibitor sample) 
-:- (Y DU Co-IP protein in vehicle sample / Y DU lP protein in vehicle sample) 
Mass spectrometry analysis 
To confirm the presence of Hsp90 in the 90 kDa protein spots cross-reacting with 
Hsp90 antibody, gel plugs containing protein spots were excized, proteins were in-gel 
trypsin digested, and digested peptides were analyzed by matrix assisted laser 
desorptionlionization time-of-flight (MALDI-ToF) mass spectrometry. 
To determine the effect of basal Akt phosphorylation on Hsp90 binding, we 
performed I-dimensional reverse phase liquid chromatography mass spectrometry-mass 
spectrometry (LC-MS-MS) analysis of trypsin digested eluted anti-Hsp90 and isotype 
control immunoprecipitates. Hsp90 was immunoprecipitated from the lysates of PC-12 
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cells pre-treated with DMSO vehicle or 20 /.!M Akti 112 for 3h and exposed to 6h of RA 
or SR. Immunoprecipitated proteins were eluted off of the beads by incubating the beads 
for 35 min with 20 mM glycine at pH 2.4, and eluants were neutralized with 1M triethyl 
ammonium bicarbonate (TEABC) at pH 8.5. LC-MS-MS analysis of equally 
immunoprecipitated anti-Hsp90 samples or isotype controls showed few proteins in 
isotype control samples, while Hsp90 immunoprecipitates were enriched in Hsp90. Thus, 
efficient immunoprecipitations were performed and peptide samples were of high quality, 
permitting identification of proteins specifically bound to Hsp90. 
Proteins were identified by peptide mass fingerprinting of tryptic peptides by 
searching the Mascot protein database (http://www.matrixscience.com).using various 
search stringency criteria, to generate a list of proteins ranked in order of greatest 
significant probability for true positive identification. The MASCOT search engine 
analyzed the entire MSDB, NCBI, and SwissProt protein databases. Peptides were 
assumed to be monoisotopic, oxidized at methionine residues, and carbamidomethylated 
at cysteine residues. Up to 1 missed trypsin cleavage was allowed. Mass tolerance of 
100 ppm was the window of error allowed for matching the peptide mass values. 
Probability based MOWSE scores estimated the significances of peptide identifications 
by comparing the calculated peptide masses for each entry in the sequence databases with 
our experimental data. These probability based scores were reported as -lO*LOG lO(P), 
where P is the probability that the observed match was a random event. Protein 
identifications were significant if they were expected to occur at random with a frequency 
of less than 5%. 
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Immunocytochemistry 
PC-12 cells at 80% confluence were cultured on Lab-Tek II Chamber Slides, and 
exposed to 6h RA or SH in the presence or absence of 20 IlM Akti 112, and then fixed 
with 3.7% paraformaldehyde for 30 min at 4°C. Fixed cells were washed twice with 
KREBS+ (Krebs-Ringer phosphate buffer, pH 7.2), permeabilized with 2% saponin for 
10 min at room temperature, and washed twice with 0.02% saponin in KREBS+. Cells 
were incubated overnight with primary antibody in 2.5% BSA, 2% donkey serum, 
0.02% saponin in KREBS+ at 4°C while shaking. Cells were washed twice with 
0.02% saponin in KREBS+, and incubated with secondary antibody in 2.5% BSA, 
2% donkey serum, 0.02% saponin in KREBS+ for 2h in the dark at 4°C. Cells were 
incubated with the nuclear stain DAPI for 10 min, washed once with KREBS+ and were 
imaged using a Zeiss Axiovert 100 M confocal microscope with LSM510 software. 
Statistical analysis 
Immunoblotting and immunoprecipitation experiments shown are representative 
of three or more experiments, unless otherwise noted. Measurements of cell viability and 
ROS production were repeated five or more times, unless otherwise noted. Statistical 
analysis was performed using the computer program, Statistical Package for the Social 
Sciences, Version 14.0 (SPSS). Data were analyzed by one-way and or two-way 
ANOV A, followed by Tukey HSD post-hoc t-tests or independent t-tests. 
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CHAPTER III: SPECIFIC AIM 1 RESULTS 
Overview 
In Specific Aim I, Hsp90-binding proteins were identified in normoxic and 
hypoxic celllysates, and the role of these proteins in PC-12 cell survival were examined 
using Geldanamycin (GA), an Hsp90 inhibitor that disrupts Hsp90 binding to proteins. 
Hsp90 was shown to regulate cellular survival by binding to the kinase co-chaperone 
Cdc37 and to the kinases, Akt and Raf-I. 
Effect of Hsp90 inhibition by Geldanamycin (GA) on PC-12 cell survival 
Hsp90~ silencing by siRNA has been infrequently used in the published literature 
to study Hsp90 chaperone function. Although siRNA silencing of Hsp90~ was attempted 
during this study, this method was abandonned due to poor siRNA transfection efficiency 
and high expression of Hsp90 in PC-12 cells. Therefore, to study the role of Hsp90 
interactions in PC-12 cell survival, Hsp90 was pharmacologically inhibited using the 
classical benzoquinone ansamycin Hsp90 ATPase inhibitor, Geldanamycin (GA). Cells 
were exposed to 10 or 20 J..lM GA or vehicle alone (DMSO) for up to 24h, and cell 
survival was assessed by MTT assay. No significant cytotoxicity occurred at Ih and 3h 
of treatment, however GA induced cell death by 6h. While both 10 and 20 J..lM GA 
induced cell death at 24h, cell toxicity induced by 20 J..lM GA was significantly higher 
when compared to the lower dose. These data suggest that GA inhibition of Hsp90 
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Figure 10. By 6h, GA induced dose- and time-dependent cell death, measured by MTT 
assay. Cells were exposed to DMSO vehicle, 10 /-lM GA, or 20 /-lM GA for the indicated 
times. The percentage of cell death was expressed as % of control MTT OD values of 
GA-treated cells vs. vehicle treated cells at the same time point. * = p < .01 for 10 /-lM 
GA vs. 20 /-lM GA at same time point, t = p < .05 for same dose of GA at different time 
points, two-way ANOV A followed by Tukey HSD post-hoc t-tests, error bars = standard 
deviations (n 2: 5). 
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Effect of GA on cell survival to hypoxia 
To determine if Hsp90 regulates cell survival to hypoxia, cells pre-treated with 20 
IlM GA or with vehicle (DMSO) for 3h, were exposed to 6h or 24h of normoxia (RA) or 
0.1 % O2 sustained hypoxia (SH), and cell survival was assessed by MTT assay. Exposure 
to 6h SH did not alter cell survival, although 24h SH resulted in hypoxic cell death. Pre-
treatment with GA induced similar cell death in normoxic and hypoxic cells by 6h of 
exposure, and this was confirmed by measuring cell viability by Trypan Blue Exclusion 
assay in parallel with MTT assay (Figure 11A). Cells pre-treated with a lower 
concentration of GA (10 IlM) died later by 24h RA and SH (data not shown). Thus, the 
effect of GA on cell survival is concentration dependent, and is not altered by SH. These 
data suggest that Hsp90 plays a general role in cellular survival rather than a role in 
cellular survival to hypoxia, and that cellular responses to 6h SH do not protect against or 
exacerbate GA cytotoxicity. 
Effect of GA on reactive oxygen species (ROS) production and ROS-mediated 
cytotoxicity 
GA disrupts Hsp90 function by interfering with its ATPase function. However, 
GA harbors a quinone group that may contributes to its cytotoxicity. To determine the 
effect of this oxidative group on GA-induced cell death, ROS production was assessed, 
using the DCF assay, in GA-treated cells and compared to ROS produced by the classical 
quinone menadione (MEN; a positive control for non-specific quinone stress) at lh, 6h, 
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Figure 11. Cell survival at 6h (A) and 24h (B) of RA and SH in presence of DMSO (D) 
and 20 /-lM OA (0). Cell viability at 6h was measured by MTT and by Trypan Blue 
Exclusion assays. Cell viability at 24h was measured by MTT assay. * = p < .005 for 
MTT OD or % cell survival of OA-treated cells vs. DMSO-treated cells at the same 
exposure and time point, t = p < .001 for MTT OD of DMSO-treated 24h SH cells vs. 
DMSO-treated 24h RA cells, exposure to 6h SH did not significantly alter survival in the 
presence of OA, one-way ANOVA followed by Tukey post-hoc t-tests, error bars = 
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Figure 12. GA and MEN induced ROS production was inhibited by 1 mM NAC. Ih (A), 
6h (B), or 24h (C) with DMSO, 20 11M MEN, or 20 11M GA. ROS production was 
measured by DCF fluorescence assay. Pre-treatments: C = Control, N = NAC; 
Treatments: D = DMSO, M = MEN, G = GA. * = P < .001 for Control-----+ DMSO vs. 
other conditions, t = p < .05 for Control-----+ GA vs. Control-----+ MEN, one-way ANOVA 
followed by Tukey post-hoc t-tests, error bars = standard deviations (n > 5). 
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not shown), MEN increased ROS starting at 6h (Figure 12B), persisting at 9h, 24h, and 
27h (Figure 12; data not shown). Pre-treatment with the glutathione precursor, N-acetyl 
cysteine (NAC), decreased GA- and MEN-induced DCF fluorescence to baseline levels 
at all time points (Figure 12). Cell survival, assessed by Trypan Blue exclusion assay, 
showed no GA cytotoxicity at Ih (Figure 13A). Thus, the increase in cellular ROS at Ih 
of GA treatment was insufficient to induce cell death at this early time point. However, 
significant cell death started at 6h (Figure 13B) and increased by 24h (Figure 13C). 
Pre-treatment with NAC prevented both GA- and MEN-induced cell death (Figures 13B 
and 13C). In addition, NAC also similarly prevented GA cytotoxicity in cells exposed to 
6h SH, showing that ROS production is also required for GA cytotoxicity in hypoxic 
cells (data not shown). Therefore, GA-induced oxidative stress plays a role in the 
cytotoxicity of GA. 
Effect GA on the activation of and stability of Hsp90 binding proteins 
To determine the effect of GA on the activation and expression of the survival 
kinases Akt and ERK1I2 and of Raf-l and Cdc37, celllysates were separated and 
immunoblotted using specific antibodies to these proteins and to their phosphorylated 
forms. Both GA and MEN increased phosphorylation of Akt and ERKI12 at Ih treatment, 
and these phosphorylations were inhibited by NAC, while total expression of these 
kinases was not altered by GA, MEN, and NAC. Therefore, these drugs may induce an 
early stress response prior to cell death (Figure 14A). Increased phosphorylation of 
ERK 112, but not of Akt was sustained at 6h treatment, coinciding with the onset of cell 
death, while total expression of Akt and Raf-l was reduced (Figure 14B). Later at 24h, 
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Figure 13. GA and MEN induced cell death was inhibited by 1 rnM NAC. Ih (A), 6h 
(B), or 24h (C) with DMSO, 20 /-lM MEN, or 20 /-lM GA. Cell survival was measured by 
Trypan blue exclusion assay. Pre-treatments: C = Control, N = NAC; Treatments: 
D = DMSO, M = MEN, G = GA. * = P < .05 for Control ----.. 6h DMSO vs. other 6h 
treated cells, * = p < .001 for Control ----.. 24h DMSO vs. other 24h treated cells, one-way 
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Figure 14. NAC (1 rnM) inhibited GA- and MEN-induced decreases in the expression of 
Hsp90-binding proteins and other proteins. Ih (A), 6h (B), or 24h (C) with DMSO, 
20 /-lM MEN, or 20 /-lM GA. Lysates were immunoblotted for Hsp90, Cdc37, 
phospho-Ser473 Akt, Akt, Raf-l, phospho-ERKI/2, ERKl, and p-actin. Pre-treatments: 
C = Control, N = NAC; Treatments: D = DMSO, M = MEN, G = GA (n 2: 3). 
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specific, affecting proteins that may not bind to the Hsp90 complex, such as p-actin and 
ERKI (Figure 14C). These GA- and MEN-induced phosphorylation increases, suggestive 
of activation of kinases, as well as total protein degradation, were inhibited by NAC, 
suggesting that oxidative stress plays a role in GA- and MEN-induced protein 
degradation (Figure 14). These data suggest that GA-induced quinone stress increases 
protein oxidation that may enhance protein ubiquitination and degradation. 
GA- and MEN-induced uhiquitination and degradation of proteins 
Both GA and MEN similarly increased total protein ubiquitination at Ih and 6h, 
indicating that the onset of protein ubiquitination occurs prior to the decrease in protein 
expression (Figure 15). NAC inhibited these increases in ubiquitination (Figure 15), 
suggesting that oxidative stress induced by these quinones increases protein 
ubiquitination. 
Effects of SH on GA-induced degradation of Hsp90-hinding proteins 
In addition to its effect on proteins function and stability in normoxic cells, Hsp90 
may also regulate the activation and stability of its binding proteins in hypoxic cells. To 
investigate the effects of Hsp90 function on the stabilization of its binding proteins in SH, 
cells were pre-treated with 20 j.lM GA or DMSO for 3h, and exposed to 6h or 24h of RA 
or SH. Inhibition of Hsp90 increased protein ubiquitination by 6h, particularly at RA, and 
induced protein degradation at 6h and 24h of RA and SH (Figure 16), that correlated with 
comparable levels of cell death at RA and SH (Figures 10 and 11). Exposure to 6h SH 
induced an increase in Ser473 Akt phosphorylation that was not affected by GA 
pre-treatment (Figure 16), although GA decreased total Akt expression. In contrast, GA 
decreased phospho-Akt levels at 6h RA. Thus, while Akt degradation is similar in 
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Figure 15. NAC (l mM) inhibited GA- and MEN-induced ubiquitination of proteins. 
Ih (A) or 6h (B) with DMSO, 20 mM MEN, or 20 mM GA. Lysates were irnmunoblotted 
for ubiquitin. Pre-treatments: C = Control, N = NAC; Treatments: D = DMSO, 
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Figure 16. Representative immunoblots of lysates show the effects of DMSO vehicle, 
20 IlM GA, and 6h and 24h RA or SH on phosphorylation of Akt and expression of 
ubiquitinated proteins, Hsp90 complex proteins, ERKl, and p-actin. D = DMSO, G = GA 
(n ~ 3). 
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GA-treated normoxic and hypoxic cells, GA does not prevent SH-induced Akt 
phosphorylation. These results suggest that, although in normoxic cells GA lowers Akt 
phosphorylation, 6h SH induces Akt phosphorylation independently from Hsp90 
function. Total expression of Akt and Raf-l decreased with GA at 6h RA and SH, while 
Hsp90, Cdc37, ~-actin, and Erk 1 expressions were only affected at 24h (Figure 16). 
Except for its effects on phospho-Akt, SH did not otherwise alter GA-induced changes in 
the expression Hsp90 complex proteins, although 24h SH decreased expression of Akt 
and Raf-I in DMSO-treated cells. 
Role of proteasomal degradation in GA-induced cytotoxicity 
Hsp90 has been reported to protect its binding proteins from proteasomal 
degradation. Therefore, the effects of GA on proteasomal degradation of normoxic and 
hypoxic Hsp90 complex proteins were investigated, using the proteasome inhibitor 
MG-132 (150 nM for 24h), followed by 20 ~M GA, or 20 ~M MEN, or DMSO for 3h. 
Following treatments, cells were exposed to 6h or 24h of RA or SH. In addition, as GA 
induces ROS as early as Ih, cells were pre-treated with MG-132 or DMSO and treated Ih 
with 20 ~M GA or DMSO at RA to detect early stages of protein degradation. Cell 
lysates were immunoblotted for ubiquitin, Hsp90, Hsp90-binding proteins, ERKI, 
~-actin, and the endogenous cytosolic antioxidant, superoxide dismutase I (SOD-I). 
Immunoblots of SOD-l showed that 150 nM MG-132 did not alter the expression of 
SOD-I (Figure 17; data not shown), although 100 nM MG-132 is known to increase 
expression of the cellular antioxidants SOD-I, SOD-2, and catalase by 2 weeks in 
undifferentiated PC-12 cells [163]. Thus, the effects of 150 nM MG-132 on protein 
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Figure 17. Representative imrnunoblots of lysates show that MG-132 and GA increase 
the expression of ubiquitinated proteins (A) without altering expression of the cytosolic 
antioxidant superoxide dismutase 1 (SOD-I ) (B) and ~-actin (A and B). Cells were 
exposed to 2Ih pre-treatments with DMSO or 150 nM MG-132 and treated for Ih with 
DMSO or 20 ~M GA (n = 3). 
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MEN and GA increased protein ubiquitination, and MG-132, by preventing proteasomal 
degradation of these ubiquitinated proteins, further increased their accumulation (Figures 
17 and 18). Both GA and MEN enhanced the degradation of Hsp90-binding proteins in 
RA and SH (Figure 18). Although both compounds are quinones, MEN and GA differ in 
that only GA disrupts Hsp90-binding. In addition, MEN-induced decreases in Hsp90, 
Cdc37, Akt, Raf-l, ERKl, and B-actin expression were inhibited by MG-132, 
demonstrating that MEN induces proteasomal degradation of these proteins (Figure 18). 
In contrast, GA-induced decreases in the expression of Hsp90, Cdc37, Akt, Raf-l, ERKl, 
and B-actin were not altered by MG-132 (Figure 18). Thus, disruption of Hsp90 binding 
by GA allows for the degradation of proteins by a proteasome-independent pathway. 
Therefore, we examined whether GA induces lysosomal degradation of Akt, 
Raf-l, and Hsp90, by pre-treating cells for 30 min with DMSO or 750 nM Bafilomycin 
Al (BAF), prior to 6h treatments with DMSO, 20 ~M MEN, or 20 ~M GA. Immunoblots 
of celllysates suggest that lysosomes are not involved in the degradation of Akt, Raf-l, 
and ubiquitinated proteins (data not shown). The role of Hsp90 binding in regulating 
protein degradation by the calpain and caspase cysteine protease pathways has not been 
examined. Thus, future studies may focus on the role of Hsp90 binding in these 
alternative protein degradation pathways. 
To determine whether GA- and MEN-induced decreases in the expression of 
Hsp90 complex proteins correlates with cell death, the effects of MEN and GA on cell 
survival were assessed by MTT assay. MEN and GA cytotoxicities correlated with 
decreased expression of Hsp90 complex proteins at 6h and 24h of RA and SH, indicating 
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Figure 18. Representative immunoblots of lysates show the effects ofMG-132, MEN, 
GA, and SH on expression of ubiquitinated proteins, Hsp90 complex proteins, ERKl, and 
~-actin. D = DMSO vehicle, MG = MG-132, M = MEN, G = GA (n = 3). 
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Figure 19. Cell survival at 6h RA and SH in the presence or absence of DMSO, MEN, 
and GA. Cell viability was measured by MTT assay. D = DMSO vehicle, MG = MG-132, 
M = MEN, G = GA. * = P < .005 for MTT OD of DMSO-pre-treated vs. MG-132-
pre-treated cells with same treatment at the same exposure, t = p < .05 for MTT OD of 
DMSO + DMSO-treated cells vs. cells at the same exposure, one-way ANOV A followed 
by Tukey post-hoc t-tests, error bars = standard deviations (n > 5). 
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Figure 20. Cell survival at 24h RA and SH in the presence or absence of DMSO, MEN, 
and GA. Cell viability was measured by MTT assay. D = DMSO vehicle, MG = MG-132, 
M = MEN, G = GA. * = P < .01 for MTT OD of DMSO-pre-treated vs. MG-132-
pre-treated cells with same treatment at the same exposure, t = p < .01 for MTT OD of 
DMSO + DMSO-treated cells vs. cells at the same exposure, one-way ANOV A followed 
by Tukey post-hoc t-tests, error bars = standard deviations (n > 5). 
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protein degradation, although the mechanisms mediating degradation and cell death 
appeared to be different. To determine whether proteasomal degradation of proteins 
results in ROS induction, DCF fluorescence levels were determined in cells treated with 
the proteasome inhibitor MG-132, prior to their exposure to GA or MEN, and compared 
to controls. MG-132 increased accumulation of ubiquitinated proteins (Figures 17 and 
20) and prevented MEN-induced increases in ROS (Figure 21 and 22), protein 
degradation, and cell death (Figures 19 and 20). In contrast, MG-132 did not alter 
GA-induced ROS (data not shown), decreases in expression of Hsp90, Cdc37, Akt, 
Raf-l, ERKl, and ~-actin (Figure 18), and GA cytotoxicity (Figures 19 and 20). These 
findings suggest MEN induces oxidative stress, resulting in proteasomal protein 
degradation, that increases ROS and cytotoxicity, without disrupting Hsp90 binding. In 
contrast, GA cytotoxicity involves disruption of Hsp90 binding and requires oxidative 
stress. Furthermore, accumulation of ubiquitinated proteins when proteasomal 
degradation was inhibited in GA-exposed cells (Figures 17 and 18), may be attributed to 
proteasomal degradation of proteins unrelated to the Hsp90 complex. GA may induce 
degradation of Hsp90-binding proteins by a non-proteasomal degradation pathway. 
Effect of GA on Hsp90 binding to client proteins 
To determine whether oxidative stress, that induces protein degradation, plays a role 
in GA-induced disruption of the Hsp90 complex, Hsp90 was immunoprecipitated from 
lysates of cells treated with GA, MEN, or the vehicle DMSO, with or without NAC 
pre-treatment. Immunoblots of Hsp90 immunoprecipitates show that 1 h GA treatment 
decreased Cdc37 and Raf-l binding to Hsp90, while MEN did not affect their binding 
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Figure 21. Reactive oxygen species (ROS) production at 6h RA and SH in the presence 
or absence of DMSO, MEN, and GA. ROS production was measured by DCF 
fluorescence assay. D = DMSO vehicle, MG = MG-132, M = MEN, G = GA. * = P < .05 
for DCF fluorescence of DMSO-pre-treated vs. MG-132-pre-treated cells with same 
treatment at the same exposure, t = p < .001 for DCF of DMSO + DMSO-treated cells 
vs. cells at the same exposure, one-way ANOV A followed by Tukey post-hoc t-tests, 
error bars = standard deviations (n > 5). 
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Figure 22. Reactive oxygen species (ROS) production at 24h RA and SH in the presence 
or absence of DMSO, MEN, and GA. ROS production was measured by DCF 
fluorescence assay. D = DMSO vehicle, MG = MG-132, M = MEN, G = GA. * = P < .05 
for DCF fluorescence of DMSO-pre-treated VS. MG-132-pre-treated cells with same 
treatment at the same exposure, t = p < .001 for DCF of DMSO + DMSO-treated cells 
vs. cells at the same exposure, one-way ANOVA followed by Tukey post-hoc t-tests, 
error bars = standard deviations (n > 5). 
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12A), did not reverse the Ih GA-induced disruption of Hsp90 binding to Raf-l and 
Cdc37 (Figure 23). Thus, GA-induced disruption of Hsp90 binding appears independent 
from its effect on cellular oxidative status at this early time point, as NAC did not prevent 
this dissociation. These findings were confirmed by immunoprecipitation of 
Hsp90-binding proteins, followed by immunoblotting for Hsp90 and Hsp90-binding 
proteins. Cdc37 dissociated from Hsp90 and Akt by lh of GA treatment independently of 
oxidative stress, as demonstrated by immunoblots of Cdc37 and Akt immunoprecipitates 
(data not shown). In addition, GA dissociated Akt from Hsp90 by 24h (data not shown). 
Longer GA treatments increased dissociation of the Hsp90 complex, while MEN still 
failed to affect protein binding (Figure 24). Therefore, while sufficient to induce cell 
death starting at 6h, oxidative stress alone, as induced by MEN, does not disrupt Hsp90 
complexes. NAC did not prevent GA-induced early protein dissociation, but allowed 
re-association of proteins with Hsp90 by 24h. 
Effect of hypoxia on Hsp90 binding and expression of binding proteins in hypoxia 
During SH, Hsp90 binding may be altered and may regulate the expression of Akt 
and of other Hsp90-binding proteins. Therefore, we examined the effects of GA on 
Hsp90 binding by immunoprecipitating Hsp90 from the lysates of cells treated with 
DMSO or 20 JlM GA for 3h and exposed to 6h or 24h of RA or SH. Hsp90 
immunoprecipitates were immunoblotted for Akt, Raf-l, Cdc37, and Hsp90. 
Immunoblots of Hsp90 immunoprecipitates show that Akt, Raf-l, and Cdc37 bind to 
normoxic and hypoxic Hsp90 complexes (Figure 25). Densitometry analysis of these 
immunoprecipitates demonstrated that GA disrupted Hsp90 binding to Raf-l and Cdc37 
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Figure 23. Representative immunoblots of Hsp90 immunoprecipitates show that at Ih of 
treatment, GA-induced disruption of Cdc37 and of Raf-l binding to Hsp90 was not 
modified by NAC, while MEN did not disrupt Hsp90 binding. Pre-treatments: 
C = Control, N = NAC; Treatments: D = DMSO, M = MEN, G = GA. IgG = control 
immunoprecipitation with non-immune isotype control antibody (n = 3). 
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Figure 24. Representative immunoblots of Hsp90 immunoprecipitates show the effects 
of control growth medium or 1 rnM NAC pre-treatments and 6h and 24h treatments with 
DMSO, 20 /-lM MEN, or 20 /-lM GA on Hsp90 binding. Pre-treatments: C = Control, 
N = NAC; Treatments: D = DMSO, M = MEN, G = GA. IgG = control 
immunoprecipitation with non-immune isotype control antibody (n 2: 3). 
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Figure 25. Representative immunoblots of Hsp90 immunoprecipitates show Akt, Raf-l , 
and Cdc37 bind to normoxic (RA) and hypoxic (SH) Hsp90 complexes. PC-12 cells were 
pre-treated with DMSO or 20 j.lM GA for 3h and exposed to 6h or 24h of RA or SH. 
Hsp90 was immunoprecipitated from lysates, and immunoprecipitates were 
immunoblotted for Hsp90, Cdc37, Akt, and Raf-I. D = DMSO vehicle, 
GA = Geldanamycin (n 2: 3). 
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in 6h RA and SH cells, while Akt binding to Hsp90 was disrupted later by 24h RA and 
SH. 
As the expression of Hsp90-binding proteins decreases in SH, we examined 
whether SH disrupts Akt, Raf-l, and Cdc37 binding to Hsp90, and whether disruption of 
Hsp90 binding by GA increases SH-induced protein degradation. GA affected Akt 
binding to Hsp90 differently at RA and SH (Figure 25). Pre-treatment with GA at 6h RA 
increased Akt binding to Hsp90, while this binding was disrupted at 6h SH. Additionally, 
GA increased protein ubiquitination peaking at 6h, particularly at RA and induced protein 
degradation at 6h and 24h of RA and SH (Figure 18), that correlated with cell death 
(Figures 19 and 20). Total expression of Akt and Raf-l decreased with GA at 6h RA and 
SH, while Cdc37, ~-actin, and Erkl expressions were affected at 24h (Figure 18). 
Therefore, Hsp90 binding may stabilize Raf-l and Cdc37, as disruption of their binding 
to Hsp90 correlates with decreased expression of these proteins. Akt expression also 
decreased in GA-treated cells at 6h RA, despite its increased binding to Hsp90. While 6h 
SH increases Akt binding to Hsp90, combining GA treatment with hypoxic stress results 
in disruption of Akt binding and its degradation. This disruption of Akt binding by GA 
combined with hypoxic stress, may allow for an increase in Akt phosphorylation that is 
decreased at 6h RA (Figures 16 and 25). 
In conclusion, Hsp90 regulates binding protein stability similarly at RA and SH. 
Hsp90 stabilization of its binding proteins positively regulates cellular survival 
independently of molecular oxygen levels, and Hsp90 inhibition by GA induces cell 
death by disruption of Hsp90 binding (Figure 26). In addition, oxidative stress induced by 










Figure 26. Hsp90 binding regulates PC-12 cell survival by regulating the degradation of 
Hsp90-binding proteins. We used the exogenous antioxidant precursor N-acetyl cysteine 
(NAC) to show that GA induces cell death by oxidative stress and by disrupting Hsp90 
binding. The degradation of proteins that is increased by this oxidative stress and by 
disruption of Hsp90 binding may contribute to cell death. 
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(Figure 26). Furthermore, these studies also suggest that proteins that are dissociated 










Figure 27. Hsp90 binding may regulate PC-12 cell survival by regulating the non-
proteasomal degradation of Hsp90 complex proteins. MEN, which did not disrupt Hsp90 
binding, induced cytotoxicity via oxidative stress and proteasomal degradation. In 
contrast, disruption of Hsp90 binding by GA allowed proteins to be degraded by an 
alternative pathway. Inhibiting proteasomal degradation did not alter GA cytotoxicity, 
suggesting that the non-proteasomal pathway contributes to cell death. 
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CHAPTER IV: SPECIFIC AIM 2 RESULTS 
Overview 
Specific Aim 2 examined whether Akt and Akt-dependent phosphorylation events 
regulate protein binding to the Hsp90 complex and cell survival. Basal Akt 
phosphorylation was shown to positively regulate cell survival. In response to hypoxia, 
Akt phosphorylates Hsp90 and Hsp90 binding to Akt, Raf-l, and Cdc37 increases. 
However, this study cannot confirm that these hypoxia-induced changes in the Hsp90 
complex playa role in cellular survival to hypoxia. Additional factors besides Akt 
expression and phosphorylation may be critical to survival to hypoxia. 
Increased Akt phosphorylation is not sufficient for survival to hypoxia 
Exposure of PC-12 cells to 6h of 0.1 % O2 sustained hypoxia (SH) increased Akt 
phosphorylation (Figure 28A), without inducing significant cell death (Figures 28B). 
Later by 24h, SH induced cell death (Figure 28B), that coincided with decreased Akt 
expression and phosphorylation (Figure 28A). Equal loading of proteins was verified by 
Ponceau-S staining of nitrocellulose membranes and by immunoblotting these 
membranes for p-actin. 
Survival kinases are activated in response to stress to promote survival pathways. 
To determine whether increased Akt phosphorylation at 6h SH is critical for cell survival 
to SH, cells were pre-treated with the Akt inhibitor, Akti 1/2 (1 ~M), prior to exposures to 
6h or 24h of normoxia (RA) or SH. At this dose, Akti1l2 inhibited the 6h SH-induced 
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Figure 28. Inhibition of 6h SH-induced phosphorylation of Akt by a low dose of Akti1l2 
did not alter PC-12 cell survival. Cells were pre-treated with DMSO vehicle or 
1 ~M Akti 112 for 3h, and exposed to 6h or 24h of normoxia (RA) or 0.1 % O2 sustained 
hypoxia (SH). (A) Representative immunoblots of celllysates show expression of 
phospho-Ser473 Akt, Akt, and ~-actin. (B) Cell viability was measured by MTT assay. 
* = p < .05 for MTT optical density (OD) of 24h RA VS. 24h SH, two-way ANOV A 
followed by Tukey post-hoc t-tests, error bars = standard deviations (n 2: 5). 
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28A). Preventing the increase in Akt phosphorylation at 6h SH neither resulted in 
significant cell death, nor altered Akt and B-actin expression (Figure 28). Additionally, 
inhibition of increased Akt phosphorylation at 6h SH did not increase cell death at 24h 
SH (Figure 28). Thus, the SH-induced increase in Akt phosphorylation at 6h SH does not 
appear to improve survival to SH, but may nonetheless promote the onset of a stress 
response. Alternatively, activation of additional pathways may compensate for the 
inability of cells to increase Akt activity at 6h SH. 
Basal Akt phosphorylation is critical for survival 
We examined whether complete inhibition of Akt kinase activity with a higher 
dose of Akti 112 inhibitor (20 IlM) would affect survival. The inhibitor at this dose 
completely abrogated Ser473 phosphorylation of Akt, while being still specific to Akt. 
The phosphorylation of ERKl/2 and the expression of Akt, B-actin (Figure 29A), Hsp90, 
and Hsp90-binding proteins were not altered by Akti1l2 (data not shown). Cell survival 
was drastically decreased by 20 IlM Akti1l2 at RA and SH, and SH did not alter the 
cytotoxicity of Akti 112 (Figure 29B), demonstrating that basal phosphorylation of Akt is 
required for cell survival regardless of molecular oxygen levels. 
Sustained Akt activation is not sufficient to protect against hypoxic cell death 
Loss of function experiments indicated that the increase in Akt phosphorylation at 
6h SH did not appear to underlie cell survival to SH, but that Akt activity was still 
essential to PC-12 cell survival. Therefore we examined whether gain of function 
experiments, inducing sustained Akt activity at 24h SH, would rescue the cells from 
SH-induced cell death. Cells were transfected with empty vector plasmids or with 
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Figure 29. Inhibition of basal phosphorylation of Akt by a high dose of Akti 112 
decreased PC-12 cell survival to 6h RA and SR. Cells were pre-treated with DMSO 
vehicle or 20 ~M Akti 112 for 3h, and exposed to 6h of RA or SR. (A) Representative 
immunoblots of celllysates show expression of phospho-Ser473 Akt, Akt, and ~-actin . 
(B) Cell viability was measured by MTT assay. * = p < .05 for MTT OD of DMSO-
treated vs. Aktill2-treated cells at the same exposure, one-way ANOVA followed by 
Tukey post-hoc t-tests, error bars = standard deviations (n > 5). 
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myristoylated Akt (CA Akt)-encoding plasmids, and exposed to 24h of RA or SH. 
Transfection efficiency was verified by immunoblotting for phospho-Ser473 Akt, Akt, 
and c-Myc tag (Figure 30A). Overexpression of WT Akt and CA Akt did not rescue cells 
from hypoxic cell death at 24h (Figure 30B). These data suggest that while Akt activation 
is required for survival, it is not sufficient to maintain survival after a long duration of 
oxygen deprivation, and that additional cellular responses may be required to rescue the 
cells at this time point. Indeed, after 24h SH, cellular respiration may be critically 
impaired and cytotoxic reactive oxygen species may be released that may damage 
proteins beyond repair. Indeed, protein expression after 24h was lower in SH than in RA, 
even after cell transfection to overexpress Akt constructs (Figure 30A). 
Hypoxia induces a transient increase in protein binding to Hsp90 that correlates 
with increased phosphorylation of Akt 
To determine whether hypoxia alters Hsp90 binding to Akt, Raf-l, and Cdc37, 
Hsp90 immunoprecipitates from cells exposed to 6h and 24h of RA or SH were 
immunoblotted for these binding proteins. SH first increased the binding of Akt, Raf-l, 
and Cdc37 to Hsp90 at 6h (Figure 25). Akt immunoprecipitation confirmed increased Akt 
binding to Hsp90 in response to 6h SH, and increased co-localization of Akt with Hsp90 
at 6h SH was also visualized by immunocytochemistry (Figure 31). However, binding of 
Akt and Raf-l approached baseline normoxic levels by 24h SH, while Cdc37 binding was 
below baseline by 24h SH (Figure 25). 
Akt phosphorylates Hsp90 in vitro and ex vivo 
Akt phosphorylation at 6h SH coincides with increased Hsp90 binding to its client 
proteins (Figures 25 and 28). Therefore, we investigated whether Hsp90 is an Akt 
66 
(A) TR V WT CA TR V WT CA 
Akt Akt Akt Akt 





• .. . TR V WT CA TR V WT CA 
Akt Akt Akt Akt 
RA RA RA RA SH SH SH SH 
Figure 30. Transfection ofPC-12 ceJls with c-Myc tagged wild type Akt (WT Akt) or 
constitutively active Akt (CA Akt)-encoding DNA plasmids did not rescue cells from 
24h SH-induced cell death. Transfection conditions: TR = mock transfection with 
transfection reagent, V = transfection of empty vector plasmids, WT Akt = transfection 
of wild type Akt plasmids, CA Akt = transfection of constitutively active Akt plasmids; 
Exposures: RA = 24h RA, SH = 24h SH. (A) Representative immunoblots of celllysates 
show expression of phospho-Ser473 Akt, Akt, and c-Myc tag, demonstrating efficient 
transfection. (B) MTT assay measured cell viability, and the average MTT OD was 
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Figure 31. Confocal microscopy images of PC-12 cells co-immunostained for Akt (red) 
and Hsp90 (green) show that 6h SH increases Akt co-localization with Hsp90 at the cell 
periphery, which is in agreement with Akt immunoprecipitation data. 
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substrate in vitro as well as in PC-12 cells. Autoradiographs of I-D SDS PAGE separated 
in vitro kinase assays showed that recombinant active human Akt autophosphorylates and 
phosphorylated recombinant human Hsp90~ (Figure 32A). The Akt inhibitory peptide 
Aktide-2T (200 ~M) and not a scrambled peptide (200 ~M), inhibited these 
phosphorylations (Figure 32A). To verify that Akt phosphorylation of Hsp90 may occur 
in PC-12 cells, cells were transfected with empty vector, wild type Akt (WT Akt), or 
constitutively active myristoylated Akt (CA Akt)-encoding DNA plasmids. Celllysates 
were separated by 2-D SDS PAGE and immunoblotted for Hsp90 in order to detect an 
Akt-dependent acidic shift in the isoelectric point of Hsp90 in CA Akt transfected cells. 
Overexpression of CA Akt induced an acidic shift in Hsp90 isoelectric point, suggestive 
of Akt-dependent phosphorylation of Hsp90 (Figure 32B). 
To determine whether hypoxia induces a similar Akt-dependent phosphorylation 
of Hsp90, cells pre-treated with DMSO vehicle or 20 ~M Akti 1/2, were exposed to 6h of 
RA or SH, to induce increased Akt phosphorylation at SH. Celllysates were separated by 
2-D SDS PAGE and immunoblotted for Hsp90 and Akt. Exposure to 6h SH increased 
Akt-dependent phosphorylation of Hsp90, Akt, and Ser473 Akt, as shown by a shift of 
these proteins towards more acidic isoelectric points, that was reversed by protein 
phosphatase 2A (PP2A) treatment or by Akti1l2 pre-treatment (Figure 33). Thus, Hsp90 
is phosphorylated by Akt at 6h SH. 
Akt-dependent phosphorylation regulates Hsp90 binding at hypoxia 
We next examined whether Akt-dependent phosphorylation of Hsp90 regulates 
protein binding to Hsp90. Hsp90 was immunoprecipitated from the lysates of cells pre-





(B) Hsp90 Vector transfected PC-12 cells 
Hsp90 CA-Akt transfected PC-12 cells 
Acidic Basic 
Figure 32. Hsp90 is phosphorylated by Akt in vitro and in the lysates of PC-12 cells 
transfected with constitutively active Akt (CA Akt)-encoding plasmids. 
(A) A representative autoradiograph of an in vitro kinase assay shows in vitro Akt 
phosphorylation of recombinant human Hsp90 and autophosphorylation of Akt. 
Phosphorylations were inhibited by the Akt phosphorylation inhibitory peptide 
Aktide-2T, and not by a scrambled peptide. (B) Representative Hsp90 immunoblots of 
2-D SDS PAGE separated PC-12lysates show transfection with CA Akt induced an 
acidic shift in the isoelectric points of Hsp90. 
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Figure 33. Representative immunoblots of 2-D SDS PAGE separated Iysates show 
6h SH induces acidic shifts in Hsp90, Akt, and phospho-Ser473 Akt, that are inhibited by 
Aktil12 and by protein phosphatase 2A (PP2A). PC-12 cells were pre-treated with 
DMSO vehicle or 20 /-lM Akti1l2 and exposed to 6h of RA or SH. Prior to 2-D 
separation, lysates were treated with or without PP2A. (A) Hsp90 immunoblots. Hsp90 
was identified in two overlapping dark spots (to the right of the dashed line) at the 
predicted isoelectric point of - 5, by MALDI-ToF mass spectrometry. 
(B) Phospho-Ser473 Akt and Akt immunoblots. 
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Hsp90 and Akt immunoprecipitates show that inhibition of Akt at 6h SH by Akti1l2 
decreases Akt, Raf-I, and Cdc37 binding to Hsp90 (Figure 34). Therefore, Akt 
phosphorylation may promote Hsp90 binding to Cdc37, Akt, and Raf-l at 6h SH. In 
contrast, decreased Akt phosphorylation at 24h results in decreased Cdc37 binding to 
Hsp90 and in cell death, and minimally affected Akt and Raf-l binding to Hsp90 
compared to 24h RA levels (Figure 25). 
LC-MS-MS analysis of anti-Hsp90 and isotype control immunoprecipitates from 
6h RA and SH exposed PC-12 cells pre-treated with DMSO or 20 J..lM Akti1l2 uncovered 
additional known and novel putative Hsp90 complex protein interactions that may be 
regulated by Akt phosphorylation. Equal immunoprecipitation was verified by Hsp90 
immunoblotting of the immunoprecipitates prior to further analysis (data not shown). 
Few proteins were identified in isotype control immunoprecipitates, while Hsp90 
immunoprecipitates were enriched in Hsp90. Thus, efficient immunoprecipitations were 
performed and peptide samples were of high quality, permitting reliable identification of 
proteins specifically bound to Hsp90. Putative Hsp90 complex-binding proteins were 
identified by searching the Mascot protein database, using various search stringency 
criteria, to generate a list of proteins ranked in order of greatest significant probability for 
true positive identification. Many of the identified Hsp90 complex proteins associated 
and dissociated from Hsp90 in response to 6h SH, suggesting that Hsp90 protein binding 
was altered by SH. A total of 81 proteins were identified among the 6h RA + DMSO and 
6h SH + DMSO Hsp90 immunoprecipitates. 40% of these proteins were identified only 
in normoxic Hsp90 complexes and 44% of proteins were identified only in hypoxic 
Hsp90 complexes, while only 16% of proteins were bound to Hsp90 in both normoxia 
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(A) IP: Hsp90 (8) IP: Akt 
6hSH 6h SH 







Figure 34. Representative imrnunoblots of Hsp90 (A) and Akt (B) imrnunoprecipitates 
show inhibition of basal Akt phosphorylation by Akti 112 decreases binding of proteins to 
Hsp90 at 6h SH. D = DMSO, Akti1l2 = 20 /-lM Akti1l2 (n = 3). 
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and hypoxia (Figure 35A). Identified Hsp90-binding proteins included proteins regulating 
processes that are altered by SH such as transport of proteins, calcium-dependent 
exocytosis, and glycolysis (Figure 35). Alterations in these protein interactions with 
Hsp90 by SH and or by Akt activation may playa role in cellular response to hypoxia. 
The motor transport protein, cytosolic dynein heavy chain (Dynein) has previously been 
reported to interact with Hsp90 complexes [164-166] and was identified only in SH 
samples (Figure 35A). Thus, SH may positively regulate the Dynein-Hsp90 complex 
interaction. Additional proteins that may be recruited to the complex in response to 6h 
SH, included the voltage-dependent L-type calcium channel, Rab3 interacting molecule 1 
(Rab3-IMl), and the trafficking protein Ras-related protein (Rab2), that transports 
proteins from the endoplasmic reticulum to the Golgi complex [167] (Figure 35A). 
MUltiple proteins were released from Hsp90 complexes in response to 6h SH, such as 
SNAP25-interacting protein (SNIP) and Rab3-interacting molecule 2 (Rab3-IM2), both 
regulators of calcium-dependent exocytosis [168, 169] (Figure 35A). In addition, a 
potassium voltage-gated channel and the glycolytic enzymes phosphofructokinases PFKl 
and PFK2, known to be activated by hypoxia, were released from Hsp90 binding in 
response to 6h SH (Figure 35A). 
Overall, a grand total of 90 different proteins were identified in Hsp90 
immunoprecipitates from lysates obtained from our four experimental conditions. The 
majority (84%) of these proteins may be regulated by both SH and Akt phosphorylation, 
suggesting that Akt phosphorylation plays a role in SH-induced alterations in Hsp90 
binding (Figure 35B). Recruitment of proteins to Hsp90 complexes in response to SH 
was altered by Aktil12. The aforementioned Dynein-Hsp90 complex interaction was not 
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(A) RA and SH Hsp90 Complexes 
I Rab3-IM1 regulates exocytosis. I 
Rab2 transports proteins 
from ER to Golgi complex. 
Dynein is a motor 
transport protein. 
V-dep L-type Ca·2 Channel 
regulates exocytosis. 
Rab3-IM2 and SNIP regulate 
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PFK1 & 2 regulate glycolysis. 
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Rab3-IM2 (DMSO + RA) 
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Dynein (DMSO + SH) 
V-dep L-type Ca·2 Channel 
(DMSO + SH) 
V-dep T-type Ca·2 Channel 
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Figure 35. Binding of proteins to Hsp90 complexes at RA and at SH may be globally 
regulated by Akt phosphorylation. Cells were pre-treated with DMSO vehicle or 20 ~M 
Akti 112 for 3h, and exposed to 6h of RA or SH. Hsp90 was immunoprecipitated from 
lysates. Putative Hsp90 complex-binding proteins were identified by reverse phase I-D 
LC-MS-MS analysis of Hsp90 immunoprecipitates. GRIPI = glutamate receptor 
interacting protein 1; Rab2 = Ras-related protein; V-dep = voltage dependent; Rab3-IMl 
& Rab3-IM2 = Rab3 interacting molecules I & 2; SNIP = SNAP25-interacting protein; 
PFK1 & 2 = phosphofructukinases 1 & 2. (A) Proteins associated and dissociated from 
Hsp90 in response to 6h SH. A total of 81 proteins were identified in DMSO + RA and 
DMSO + SH Hsp90 immunoprecipitates. 40% of these identified proteins may bind to 
Hsp90 only at RA, and 44% of proteins may bind to Hsp90 only at SH. Only 16% of 
proteins were detected in both DMSO + RA and DMSO + SH Hsp90 complexes. 
(B) Akti 112 altered protein interactions of RA and SH Hsp90 complexes. The majority of 
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identified putative Hsp90-binding proteins may be regulated by Akt and hypoxia. 
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detected in the presence of Akti1l2 at 6h SH, suggesting that this interaction requires Akt 
phosphorylation (Figure 35B). In addition, we identified the glutamate receptor 
interacting protein (GRIPl) as a protein of high stringency hit significance that associated 
with Hsp90 complexes only in Akti 112-treated samples independently from hypoxia, 
suggesting GRIPl binds to Hsp90 when Akt phosphorylation is decreased (Figure 35B). 
Immunblots for GRIPl showed expression of GRIPl in PC-l2 celllysates was not 
altered by Akti1l2 (Figure 36), and preliminary immunochemistry of Hsp90 and GRWI 
suggest co-localization of GRIPl with Hsp90, particularly at the cell periphery (data not 
shown). The majority of Hsp90 binding proteins at RA or SH, dissociated in response to 
Akti 112, suggesting that Akt phosphorylation globally regulates the association of 
proteins with Hsp90 complexes, and modulates cellular responses to SH. In summary, 
Akt phosphorylation regulates the protein interactions of normoxic and hypoxic Hsp90 
complexes, but this study cannot confirm that Akt phosphorylation regulates survival to 















Figure 36. The putative Hsp90-binding protein GRIPl is expressed in PC-l2 cells. 
Representative irnrnunoblots show that GRIPl expression in lysates is not altered by 
6h SH or by 20 IlM Akti 112. Confocal microscopy images of PC-l2 cells 
co-irnrnunostained for GRIP! and DAPI show GRIPl chiefly localizes to the cell 
periphery, but also occurs deeper in the cell. 
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Figure 37. Akt phosphorylation of Hsp90 regulates Hsp90 binding to Akt, Raf-l, and 
Cdc37. Although Akt phosphorylation of Hsp90 and increased Hsp90 binding correlate 
with PC-12 cell survival to hypoxia at 6h, this study cannot confirm that Akt 
phosphorylation and Hsp90 binding play roles in the cellular survival responses to 
hypoxia. Instead, this study demonstrates that Akt phosphorylation and Hsp90 binding 
play roles in general cellular survival. 
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CHAPTER V: DISCUSSION 
Specific Aim 1 overview 
The protein interactions of Hsp90 complexes have been implicated in cell 
survival. Hsp90 binding has been previously shown to be required for stability and 
activation of the survival kinase Akt, and disruption of Hsp90 binding to Akt induces 
apoptosis [63, 114]. Additional Hsp90-binding proteins that may regulate cell survival 
are the kinase Raf-l and the kinase co-chaperone Cdc37, that is critical for Hsp90 
binding to kinases [107, 120, 121]. Indeed, the Raf-l-Cdc37-Hsp90 complex is essential 
to Raf-l activity and stabilization [96]. This study shows that Hsp90-dependent 
stabilization of Akt and Raf-l regulates survival of PC-12 cells. 
The mechanisms of GA cytotoxicity 
We used the classical Hsp90 inhibitor Geldanamycin to show that Hsp90 binding 
to Akt, Raf-l, and Cdc37 positively regulates cell survival by stabilizing Akt and Raf-I. 
GA induces PC-12 cell death, suggesting a role for Hsp90 interactions in survival of 
these cells. Our findings show that GA cytotoxicity correlates with decreased expression 
of Hsp90-binding proteins. Later on, at 24h SH, a general decrease in protein expression, 
including proteins that do not bind to Hsp90, occurred. GA cytotoxicity has been 
attributed to its disruption of Hsp90 binding [77]. However, the benzoquinone moiety of 
GA is a source of oxidant radicals, and the role of oxidative stress in the drug's 
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cytotoxicity and in disruption of Hsp90 binding has not been previously examined. Thus, 
using an antioxidant strategy and comparing the GA effect to that of MEN, a classical 
quinone that does not bind Hsp90, this study determined the role of oxidative stress in 
GA-induced cell death and in disruption of protein binding. Our comprehensive study of 
Hsp90 binding demonstrates for the first time a role for oxidative stress in these two 
effects of GA (Figure 26). We established that while cytotoxic, MEN-induced quinone 
stress alone was insufficient to dissociate the Hsp90 complex. We uncovered a dual 
mechanism for GA-induced cell death, that may allow improved targeting of cancer cells. 
GA induced early disruption of the Hsp90 complex and oxidation of proteins, followed 
by their degradation, resulting in cytotoxicity. These data are in agreement with a recent 
study by Fukuyo et. ai., that showed oxidative stress induced by the GA derivative 
17-demethoxygeldanamycin (l7-DMAG) is required to decrease the kinase activity and 
expression of mutant B-Raf [86]. In addition, cells treated with the GA derivative, 
17-allylamino-17-demethoxy-geldanamycin (l7-AAG), have been recently shown to 
produce ROS [170]. 
Developing antioxidant and GA analog therapies for the treatment of cancer 
Therefore, the cytotoxicity of GA and its derivatives can be modulated using 
antioxidant compounds, so that Hsp90 binding can be transiently disrupted without 
altering cellular redox state, allowing for the targeting of Hsp90 and its binding proteins 
in Hsp90 and kinase over-expressing cancer cells [72], while potentially minimizing 
toxicity to non-cancerous cells. However, this strategy needs to be modulated to fit the 
variability of cancer cell tolerance to oxidative stress. Indeed, some cancer cells are 
sensitive to oxidative stress while others, especially metastatic cancer cells, are resistant 
81 
to oxidative stress [171]. High levels of the endogenous antioxidant peptide glutathione 
(GSH) and Hsp25, which positively regulates GSH levels, are associated with the 
resistance of cancer cells to GA cytotoxicity [172]. Additionally, GSH levels regulate 
cancer cell resistance to radiation therapy [171]. Although GA was initially discovered as 
an Hsp90-targeting drug, GA and MEN are among several anticancer drugs known to 
also decrease GSH [83, 84]. Furthermore, adding the antioxidant NAC may increase 
cancer cell proliferation [173] and decrease GA analog toxicity in cancer cells. However, 
more advantageous antioxidants may instead sensitize cancer cells to hepatotoxic GA and 
its analogs, while exhibiting minimal toxicity in non-cancerous cells. The 
metalloporphyrin manganese superoxide dismutase (MnSOD) mimetic, MnTBAP, is 
such an alternative antioxidant [174], that induces cancer cell death by increasing H20 2 
[173], yet inhibits cardiotoxicity induced by the anthraquinone derivative 
chemotherapeutic, Doxorubicin [175], and acute liver failure [176]. In addition, the 
antioxidant properties of MnTBAP may be chemopreventive against esophageal 
adenocarcinoma [177]. Alternatively, the recent development of the Hsp90-hinding 
non-quinone analog of GA, analog 5 of macbecin, may provide cancer therapies that are 
less toxic to normal cells [178]. Benzoquinone ansamycin Hsp90 inhibitors may induce 
cancer cell death by inducing the degradation of oxidized Hsp90-binding proteins that 
have dissociated from Hsp90. Whether non-quinone ansamycin Hsp90 inhibitors may 
induce similar toxicity in cancer cells in the absence of oxidation of dissociated binding 
proteins remains to be investigated. However, our current study demonstrates that 
increased ROS production by GA is required for its cytotoxicity. 
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The mechanism of quinone-induced phosphorylation of kinases 
In this study, the quinones GA and MEN induced an increase in the 
phosphorylation of Akt and ERK1I2 prior to a decrease in total expression of these 
kinases. Quinones may induce kinase phosphorylation by generating reactive oxygen 
species (ROS), that increase epidermal growth factor receptor (EGFR) signaling [179]. 
Singlet oxygen e02), an electronically excited form of molecular oxygen that reacts with 
free radicals, may also increase signaling of receptor tyrosine kinases by inhibiting 
inhibitory protein tyrosine phosphatases (PTPase) by oxidizing their active cysteines 
[180]. ROS induced by MEN may playa similar role in activation of EGFR and ErbB2, 
since NAC partially inhibited their activation in the keratinocyte cell line, HaCaT [179]. 
Additional mechanisms also increase phosphorylation of receptor tyrosine kinases and 
downstream kinases. In rat liver epithelial cells, MEN induces EGFR-dependent 
phosphorylation of ERK by three alternative mechanisms: (i) PTPase dephosphorylation 
ofEGFR (by alkylating the cysteine thiols of unknown PTPases) [181,182], (ii) by 
depleting cellular glutathione (by alkylation), and (iii) by redox cycling (which increases 
glutathione disulfide (GSSG)) [183, 184]. In contrast, MEN induces phosphorylation of 
Akt by an EGFR-dependent pathway in some cells and by an EGFR-independent 
pathway in other cells [185]. However, the Akt pathway may also be activated by 
reactive oxygen species (ROS) in an EGFR-dependent manner [186]. In PC-12 cells, 
ROS-induced signaling may be the predominant mechanism of GA- and MEN-induced 
increases in phosphorylation of Akt and ERK, since NAC completely inhibited these 
inducible phosphorylations. In addition, in PC-12 cells oxidative stress plays a role in the 
cytotoxicities of these two quinones. The relative roles of alkylation and oxidative stress 
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in MEN-induced kinase phosphorylation and cytotoxicity may depend on cell type. In rat 
platelets, the primary mechanism of MEN cytotoxicity is arylation rather than oxidative 
stress, although MEN is a redox cycler and an arylator [187]. 
Mechanism of decreased sensitivity of Akt phosphorylation to GA at hypoxia 
Although GA initially increased phosphorylation of Akt and ERK, the expression 
and phosphorylation of these kinases later decreased. Interestingly, at 6h of exposure, 
phosphorylated Akt in hypoxic lysates was more resistant to GA-induced 
dephosphorylation than that of normoxic lysates. The mechanism for this persistence of 
Akt phosphorylation in hypoxic cells has never been investigated. Perhaps in response to 
hypoxia, a kinase upstream of and independent of its binding to Hsp90 phosphorylated 
Akt, and so that Akt phosphorylation still increased in cells exposed to 6h SH and persists 
even in the presence of GA. Indeed, the activation of the upstream kinase Src by its 
GA-induced dissociation from Hsp90 results in activation of Akt and ERK [188]. We 
speculate that Src or another kinase is dissociated from Hsp90 by hypoxia, and that this 
dissociation enables an increase in the duration of Akt phosphorylation at 6h SH despite 
the presence of GA. 
GA-induced protein degradation is proteasome-independent in PC-12 cells 
Disrupting Hsp90 function with Hsp90 inhibitors has been reported to induce 
ubiquitination and proteasomal degradation of many of Hsp90-binding oncoproteins [77]. 
The present study suggests that increased protein ubiquitination may also result from 
protein oxidation by these quinone compounds. The chaperone function of Hsp90 
protects Akt and Raf-l from ubiquitin-dependent proteasomal degradation in the human 
cancer MCF-7 and mouse fibroblast NIH3T3 cell lines, respectively [63, 64]. 
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Furthermore, lysosomal, caspase, and calpain protein degradation pathways do not playa 
role in the degradation of Akt and Raf-l in these two cell lines [63,64]. However, these 
studies by Basso et. al. and Schulte et. al. did not examine the effects of proteasomal 
inhibition on cell viability in the presence or absence of Hsp90 inhibition. Our results 
show increased protein ubiquitination in GA- and MEN-treated PC-12 cells. Proteasomal 
inhibition prevented protein degradation and cell death in MEN-treated cells, although 
MEN did not dissociate proteins from Hsp90. In contrast, GA dissociated the Hsp90 
complex and proteasomal inhibition did not prevent GA-induced cytotoxicity and the 
degradation of some Hsp90 complex proteins. Therefore, Hsp90 binding may potentially 
affect protein degradation pathways. Proteins bound to Hsp90 may be targeted to 
proteasomal degradation, whereas proteins dissociated from Hsp90 may be degraded by 
an alternative pathway (Figure 27). Furthermore, Hsp90 inhibition by GA has been 
shown to induce proteasome-dependent internalization and subsequent lysosomal 
degradation of the receptor tyrosine kinase ErbB2, an Hsp90-binding protein localized at 
the plasma membrane [66]. 
Hsp90 may regulate chaperone-mediated autophagy 
In addition, Finn et. al. propose a role for Hsp90 in negatively regulating 
chaperone mediated autophagy (CMA). a selective process that targets specific cytosolic 
proteins for lysosomal degradation [67]. Hsp90 inhibition by GA was shown to increase 
CMA [67]. Recently, Hsp90 has been shown to bind IkB kinases as well as NFkB-
inducing kinase, regulating NFkB activation [68,69]. GA disrupted the binding of these 
kinases, resulting in their degradation by a non-proteasomal mechanism that was 
identified as autophagic degradation [68, 69, 189]. These data agree with our findings 
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that GA- dissociated Hsp90-binding proteins are degraded via a non-proteosomal 
degradation pathway. However, oxidative stress may induce CMA of oxidized proteins 
[70], and the role of GA-induced oxidative stress in CMA was not examined in these 
studies. Hsp90 binding may facilitate refolding of oxidized cytosolic proteins, preventing 
their translocation to lysosomes that only accept unfolded proteins [67]. Regulation of 
CMA by Hsp90 may playa role in cellular survival. Indeed, alterations in CMA have 
been shown in models of normal aging and the age-related neurodegenerative diseases, 
Alzheimer's Disease and Parkinson's Disease [71]. 
GA-induced protein degradation is lysosome-independent in PC-12 cells 
Our work shows that the disruption of Hsp90 binding by GA induces chiefly 
proteasome-independent degradation of many cytosolic Hsp90-binding proteins, while 
the non-specific quinone stress of MEN induces chiefly proteasomal degradation. Thus, 
the lysosome inhibitor Bafilomycin AI (BAF) was used to investigate whether lysosomal 
degradation is the non-proteasomal mechanism responsible for GA-induced degradation 
of these proteins and cell death. BAF is known to inhibit lysosome acidification at 50 nM 
concentration by 25 min in 100 ng/mL nerve growth factor (NGF)-differentiated PC-12 
cells [190]. However, up to 750 nM BAF did not alter GA-induced degradation of Akt 
and Raf-I, suggesting that these proteins are not degraded by the lysosomes when Hsp90 
binding is disrupted. 
Hsp90 binds proteins of the caspase proteolytic pathway 
Future studies will determine whether Hsp90 binding protects proteins from 
degradation by caspases and cells from caspase-dependent cell death. Caspases are 
activated in models of cerebral ischemia [191], traumatic brain injury [192], and spinal 
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cord injury [193], and caspase inhibitors are neuroprotective against neuronal cell death 
in a model of cerebral ischemia [191]. GA induces caspase-dependent apoptosis in 
human glioma cells, that correlates with decreased expression of phosphorylated Akt 
[62]. In addition, Caspase-3 has been identified as a binding protein of Hsp90, suggesting 
that Hsp90 binding may regulate caspase activation [194]. Furthermore, Hsp90 binds to 
the caspase-processed and unprocessed forms of CDKII (CDKpllO and CDKllp46, 
respectively) [108] and regulates their proteasomal degradation, suggesting that Hsp90 
may function as a scaffold for caspases and their substrates, thereby allowing substrate 
cleavage, or that Hsp90 may prevent caspase substrate cleavage by sequestering inactive 
caspases. In contrast, the broad-spectrum caspase inhibitor zVAD-fmk did not alter 
17-DMAG-induced degradation of mutant B-Raf [86]. Thus, Hsp90 may affect 
neuropathological conditions by interacting with caspase pathways and substrates. 
Designing drugs that target Hsp90 may lead to the development of novel therapies for 
these pathological conditions involving dysregulation of caspase-dependent apoptosis 
pathways. 
Hsp90 binds proteins of the calpain proteolytic pathway 
Like caspases, calpains are involved in protein degradation and in apoptosis. 
However, calpains are also implicated in necrotic cell death [195]. Alterations in 
activation of the calpain degradation pathway are associated with hypoxia-induced retinal 
neuropathologies [196] and neurodegenerative diseases, including Alzheimer's, 
Parkinson's, and Pick's diseases [197]. Recent studies have focused on the role of 
calpains in necrotic neuronal cell death in hypoxic, ischemic, and excitotoxic neuronal 
injuries [195,197]. In PC-12 cells, calpain is activated by nerve growth factor withdrawal 
87 
[198], and calpain inhibition is protective against cell death (induced by exogenous ATP 
and iron) [199]. Hsp90 has been reported to protect several kinases and enzymes from 
cal pain-dependent degradation. Hsp90 binding to both calpain and nitric oxide synthase 
(NOS) protects NOS from calpain-dependent degradation in the rat brain [200, 201]. In 
addition, resistance of NOS to calpain degradation correlates with high levels of Hsp90 
expression in cells [200,201]. Consequently, Hsp90 and calpain may regulate NOS-
dependent production of nitric oxide and superoxide oxidant species. The current study 
shows that a long duration of hypoxia may disrupt Hsp90 binding to its elient proteins. 
Therefore, during hypoxia, NOS activity may decrease due to calpain-dependent 
degradation of Hsp90 and NOS (in pulmonary artery endothelial cells (PAEC)) [202]. 
Simultaneous production of nitric oxide and superoxide results in formation of 
peroxynitrite and increased toxicity [203], that may prevent the protective effect of nitric 
oxide and underlie hypoxic cell death (in pulmonary artery endothelial cells (PAEC)) 
[202]. In addition, calpain increases proteasomal degradation of proteins [204]. Calpain 
also decreases phosphorylation of the survival kinase Akt, without altering Akt 
expression or Akt binding to Hsp90 [204]. In addition, the cyelin-dependent kinase 
Cdc25c, that regulates cell cyele at theG2/M checkpoint, is degraded by calpain and not 
by the proteasome in GA-treated glioblastoma cell lines [205]. Therefore, calpain may 
degrade some proteins independently of the proteasome and process other proteins for 
proteasomal degradation [204,205]. Future studies will determine whether the chaperone 
Hsp90 regulates survival by protecting Akt and its other binding proteins from cal pain-
dependent proteolytic degradation. 
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Hsp90 may regulate oxidative stress 
In addition, we considered whether or not Hsp90 binding regulates cell survival 
by regulating cellular oxidative stress. Nardai et. al. proposed a role for Hsp90 in 
regulating the redox state of cells by reducing proteins, and show that this function of 
Hsp90 is blocked by sulfhydryl reagents that may target the chaperone's cysteine residues 
[206]. Indeed, Hsp90 siRNA studies by Conconi et. ai. suggest that Hsp90 may protect 
the trypsin-like activity of the 20S proteasome from oxidative inactivation [207]. 
However, Nardai et. ai. did not examine whether or not this novel putative function of 
Hsp90 regulates cell survival. GA and MEN may act as sulfhydryl reagents by oxidizing 
critical cysteine residues of Hsp90, and may thereby inhibit the ability of Hsp90 to 
regulate cellular oxidative stress, resulting in oxidative stress-dependent cytotoxicity. 
However, we cannot distinguish between the effects of disruption of Hsp90 binding by 
GA and the non-specific effects of the quinone moiety on cellular ROS. In PC-12 cells, 
undisrupted Hsp90 binding is not sufficient to restore baseline redox state in presence of 
MEN. Thus, we cannot confirm that Hsp90 regulates cellular redox state. 
Cancer alters the Hsp90 complex 
A variety of pathological conditions may alter Hsp90 binding and the extent to 
which these protein interactions control cell fate. Cancer cells are more sensitive than 
normal cells to the cytotoxicities of Hsp90 inhibitors, and alterations in the binding of 
proteins, ATP, and ADP to Hsp90 may be the mechanisms for this difference between 
cancer and normal cells [72,208-210]. In cells, unbound Hsp90 monomers and Hsp90 
dimer complexes binding to co-chaperones and binding proteins exist in equilibrium [49]. 
89 
In cancer cells, this equilibrium may be shifted towards the Hsp90 complexes, increasing 
cancer cell sensitivity to Hsp90 inhibitors that disrupt the Hsp90 complex [49]. 
Hypoxia alters the Hsp90 complex 
Recently, Chiosis and Neckers speculated that hypoxia may also alter the binding 
of proteins to Hsp90 in cancer cells may be altered by hypoxia [49]. Indeed, hypoxia has 
been shown to regulate Hsp90 binding in non-cancerous cells. Increased binding of 
Hsp90 to nitric oxide synthase 3 (NOS3) may increase resistance to myocardial ischemia 
by increasing NOS3-dependent production of cardioprotective nitric oxide and by 
decreasing production of cytotoxic superoxide [37]. Furthermore, resistance to 
myocardial ischemia was decreased by 10 J-lM GA [37]. In addition, alterations in the 
Hsp90-NOS3 complex induced by 17.8 !AM GA increased NOS3-dependent superoxide 
production in bovine coronary endothelial cells (BCEC) [211]. Thus, it is worthwhile to 
further explore the effects of hypoxia on Hsp90 binding in cancer cells, as hypoxia may 
influence cancer cell survival by regulating the Hsp90 complex. 
Our hypoxia study showed that SH induces an increase in Hsp90 binding to Akt, 
Raf-l, and Cdc37. In contrast, Hsp90 binding to Akt and Raf-l returned to baseline while 
Cdc37 binding to Hsp90 is decreased at 24h SH, relative to RA, concomitant with 
hypoxic cell death. Thus, early and late stages of SH alter the extent to which these 
proteins bind to Hsp90. These differences may reflect a difference between the response 
of the Hsp90 complex to a short hypoxic stress and the response to a more sustained 
hypoxic stress. Furthermore, increased Hsp90 binding correlates temporally with cellular 
survival to hypoxia, although this study cannot confirm a role for Hsp90 in the survival 
response to hypoxia. 
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In addition, putative Hsp90-binding proteins identified by LC-MS-MS in hypoxic 
Hsp90 complexes and proteins related to these proteins are known to play roles in cellular 
processes that are altered by hypoxia. Hypoxia alters transport of proteins, endocytosis, 
exocytosis, and metabolism, and also plays a key role in tumor cell survival, invasion, 
and metastasis. Proteins involved in these cellular functions were identified in Hsp90 
immunoprecipitates, suggesting that the chaperone Hsp90 may regulate several of these 
functions. The Hsp90 complex may function as a scaffold protein by allowing several 
proteins from the same pathway to interact with one another while they are bound to 
Hsp90. Indeed, Hsp90 has been shown to function as a scaffold protein for signaling 
pathways that interact with Akt and are altered by hypoxia [139, 212]. 
We identified the motor transporter Dynein as an Hsp90 complex protein only in 
hypoxic celllysates (Figure 35A). In response to 6h SH, the association of the Hsp90 
complex with Dynein may increase, allowing for translocation of Hsp90-binding proteins 
to the nucleus. Indeed, Hsp90 is known to translocate binding proteins towards the 
nucleus by interacting with Dynein complexes. The Dynein-Hsp90 complex interaction is 
known to mediate the nuclear translocations of glucocorticoid receptor and the tumor 
suppressor p53, a hypoxia-regUlated pro-apoptotic Hsp90-binding protein (Figure 38) 
[164-166]. Additionally, in pulmonary artery endothelial cells, hypoxia causes Dynein-
dependent mitochondrial translocation to the perinuclear domain that serves to create a 
nuclear oxidant stress important for hypoxic signaling [213]. Interruption of the Dynein-
dependent molecular motor using a specific siRNA prevented both the perinuclear 
mitochondrial clustering and, importantly, the hypoxia-induced nuclear oxidant stress 
[213]. Therefore, disruption of Hsp90-Dynein interaction using Hsp90 inhibitors may 
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Cytosol 
Figure 38. Cytoplasmic dynein heavy chain, identified as a putative Hsp90-binding 
protein only in lysates from 6h SH + DMSO cells, may assist Hsp90 in hypoxia-induced 
Akt-dependent translocation of its binding proteins to the nucleus. 
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relieve the cells from hypoxia-induced nuclear oxidant stress, provided that Hsp90 
inhibitor-related oxidant stress is minimal. 
In addition, we showed that the Rab pathway trafficking proteins, Rab3-IM 1 and 
Rab2, may be recruited to the Hsp90 complex in response to 6h SH. The trafficking 
protein Rab2 transports proteins from the endoplasmic reticulum to the Golgi complex 
(Figure 35A) [167]. Yoon et. al. identified a related Rab vesicle trafficking protein, 
Rab 11, as a novel target of hypoxic stimulation in breast carcinoma cells, that is 
important for tumor invasion, but not for regulation of apoptosis [214]. Rabll plays a 
role in membrane protein recycling and in the exocytosis and translocation of proteins 
from the trans-Golgi network to the plasma membrane [214, 215]. Thus, Rab3-IMI and 
Rab2 may also playa role in hypoxia-induced cancer cell invasion, but not in cellular 
survival to hypoxia. In summary, some of the Hsp90-binding proteins identified may play 
roles in survival, while others may play roles in cellular processes unrelated to survival 
that are altered by hypoxia. Ongoing proteomics studies will determine which of the 
novel putative Hsp90-binding proteins regulate survival. 
In addition to identifying trafficking proteins, we identified putative Hsp90-
binding proteins involved in endocytosis. Endocytosis pathway proteins recruited to the 
complex in response to 6h SH include the voltage-dependent L-type calcium channel, 
which regulates calcium-dependent endocytosis pathway. Identified proteins that may be 
released from Hsp90 complexes in response to 6h SH, such as SNAP25-interacting 
protein (SNIP) and Rab3-IM2, also regulate calcium-dependent exocytosis (Figure 35A) 
[168, 190]. 
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Furthermore, our data suggests that a potassium voltage-gated channel may be 
released from Hsp90 complexes in response to 6h SH. Previously, hypoxia has been 
shown to alter potassium channel pathways [216-218], and potassium channels are 
involved in oxygen sensing and in regulation of apoptosis [219]. Interestingly, exocytosis 
of potassium voltage-gated channels to the plasma membrane is known to be regulated by 
Rab 11, a relative of the putative Hsp90-binding Rab proteins that we identified (Figure 
35) [215]. These potassium channels may also be regulated by the idenfied calcium 
channels that is involved in endocytosis. Indeed, some potassium channels depend on 
calcium channels for activation [218, 220]. In addition, Dynein binding has been shown 
to downregulate potassium channel expression at the plasma membrane following 
channel internalization [221]. 
Hypoxia initially increases the rate of anaerobic glycolysis until ATP is depleted, 
resulting in decreased glycolysis and hypoxic cell death [222-225]. In hypoxic cardiac 
cells, the short-term increases in glycolysis are protective, but may be detrimental in the 
long term [226]. In addition, increased rates of glycolysis in cancer cells are responsible 
for promoting survival of tumor cells and for poor prognosis for cancer patients [227]. 
We identified the glycolysis enzymes phosphofructokinases PFKl and PFK2 as putative 
Hsp90-binding proteins that may be released from Hsp90 complexes in response to 6h 
SH (Figure 35A). PFK2 positively regulates PFKl and glycolysis by synthesizing the 
allosteric positive regulator of PFKl, fructose-2,6-bisphosphate (Fru-2,6-P2). Thus, 
Hsp90 may function as a scaffold protein for PFK 1 and PFK2 at normoxia, thereby 
enhancing the activation of PFKl by the product of PFK2. However, glycolysis is slower 
at normoxia than at hypoxia. Alternatively, rather than act as a scaffold, Hsp90 may 
94 
instead sequester these enzymes at normoxia, reducing their activity. Dissociation of 
PFKl and PFK2 from Hsp90 in hypoxia may activate PFKl and increase the rate of 
glycolysis, until the ATP that is needed for glycolysis is depleted. Cancer cells are known 
to have higher glycolitic rates and enhanced Hsp90 expression. 
Specific Aim 2 overview 
Our findings show that 6h SH induces Akt activation and Akt-dependent Hsp90 
phosphorylation in PC-12 cells, coinciding with enhanced Akt, Raf-l, and Cdc37 binding 
to Hsp90. While increased Akt stimulation at 6h SH was not critical for cellular survival, 
it contributed to enhance Akt, Rafl and Cdc37 binding to Hsp90. This increase in Akt 
phosphorylation and in Hsp90 binding correlated temporally with survival to hypoxia. 
However, we were unable to confirm that Akt phosphorylation and Hsp90 binding 
regulate survival to hypoxia. Thus, our study concludes that Akt phosphorylation and 
Hsp90 binding plays a role in general survival rather than in the survival responses to 
hypoxia. Inhibiting baseline Akt phosphorylation resulted in protein dissociation from the 
hypoxic complex, and in death in normoxic and hypoxic cells. In contrast, Hsp90 binding 
to Akt and Raf-l returned to baseline while Cdc37 binding to Hsp90 was decreased at 
24h SH, compared to RA, concomitant with a decrease in Akt phosphorylation and cell 
survival. Cell transfection, to express constitutively active Akt to sustain Akt activation, 
was not sufficient to prevent cell death at 24h SH, suggesting that by this time point 
hypoxic damage is irreversible. 
Akt regulates cellular functions 
Akt may regulate a broad spectrum of cellular functions that may influence 
survival, including glucose metabolism, gene transcription, cell proliferation, and 
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apoptosis [228, 229]. Akt regulates cellular survival of normoxic and hypoxic cells [9, 
230-234]. In addition, Akt activation promotes survival during cerebral ischemia [235, 
236] and ischemiaireperfusion [237-239], and protects cells from hypoxiaireoxygenation 
(H/R)-induced oxidative stress and apoptosis [240]. Pro-survival effects of Akt have been 
attributed to its regulation of and phosphorylation of the pro-apoptotic proteins Bad 
[240], caspases [107], and forkhead family transcription factions [241]. Furthermore, Akt 
prevents apoptosis by phosphorylating telomerase reverse transcriptase (TERT), an 
enzyme of telomerase that is critical to the synthesis and maintenance of telomere length 
[242]. Akt phosphorylation and TERT binding to Akt and Hsp90 is required for TERT to 
maintain its activity [242]. In addition, Akt may regulate the hypoxia-inducible survival 
pathways of vascular endothelial growth factor (VEGF) [243] and of hypoxia-inducible 
factor la (Hif-la) [244]. In agreement with another study [140], we found that Akt 
phosphorylates Hsp90. Thus, we examined whether phosphorylation of Hsp90 by Akt 
regulates Hsp90 binding to proteins that may affect cellular responses to hypoxia and 
cellular survival. 
The role of Akt phosphorylation in PC-12 cellular survival 
In PC-12 cells, mild sustained hypoxia (5% O2) has been shown to induce 
phosphorylation and activation of Akt by 6h, that persists up to 24h [6,245]. In the 
present study, PC-12 cells were exposed to severe sustained hypoxia (0.1 % O2), that 
similarly increased Akt phosphorylation by 6h, but decreased Akt phosphorylation and 
caused hypoxic cell death by 24h. Thus, Akt phosphorylation temporally correlates with 
PC-12 cell survival to hypoxia, and the findings of our study and those of Beitner-
Johnson et. al. demonstrate that the severity and duration of hypoxia differentially affect 
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hypoxia-induced Akt activation [245]. In addition, activation of the phosphatidylinositol 
3-kinase (PI3K)/Akt pathway has previously been shown to correlate with hypoxia-
induced protection of PC-12 cells from apoptosis induced by serum withdrawal and by 
chemotherapy [8].Using two different doses (1 J...lM and 20 J...lM) of the Akt inhibitor, 
Akti 112 [246], we uncovered that Akt activation regulates Hsp90 chaperone function, 
modulating cellular responses to SH. Akti 112 interacts with the pleckstrin homology 
domain of Akt, thereby preventing Akt translocation to the plasma membrane and its 
phosphorylation, without affecting its expression [246] (Calbiochem). At the doses used 
in our study (below 50 /-LM), Akti1l2 specifically targeted Akt and did not inhibit closely 
related AGC family kinases, PKA, PKC, and SGK [Ill, 247]. The lower dose of Aktil/2 
inhibited only the SH-induced increase in Akt phosphorylation, while the high dose of 
Akti 112 also inhibited basal Akt phosphorylation and affected Hsp90 protein binding, 
differentiating between the effect of SH-induced and basal Akt activation. In addition, 
this study uniquely demonstrates that, while Akt activity is required for survival, SH-
induced Akt activation is not critical to survival, although it may affect cellular adaptive 
responses to hypoxia. 
DeFeo-lanes et. al. demonstrated a role for Akt in survival of normoxic prostate 
cancer cells using a comparable Akti1l2 dose (5 /-LM), that sensitized tumor and not 
normal prostate cells to therapy-induced apoptosis [111]. Thus, Akt particularly affects 
tumor cells survival. In addition, Akti 112 has been used to show that Akt phosphorylation 
induced by the peptide Gly14-Humanin protects against hypoxia/ischemia reperfusion 
injury in a mouse model of middle cerebral artery occlusion [248]. This Akti1l2 study in 
PC-12 cells demonstrates that basal Akt phosphorylation and not hypoxia-induced Akt 
97 
phosphorylation is critical to survival. Many studies indicate that Akt signaling induced 
by a short hypoxic challenge protects cells during exposures to subsequent stressors, 
including reoxygenation, chemotherapy, and serum withdrawal. However, these studies 
did not examine cell survival during sustained hypoxia. While cell resistance to a variety 
of stressors may indeed dependent on prior hypoxia-induced Akt phosphorylation, cell 
survival during sustained hypoxia may instead require basal Akt phosphorylation, and 
Akt phosphorylation above baseline levels may not be critical. 
Sustained Akt activation is not sufficient to protect against hypoxic cell death 
In order to determine if increasing Akt phosphorylation may rescue cells from 
hypoxic cell death, we transfected PC-12 cells with wild type and constitutively active 
Akt-encoding plasmids and then exposed cells to 24h SH. Previously, transfection of a 
variety of cells with constitutively active Akt was shown to protect cells from apoptosis 
induced by a variety of stimuli [235], and transfection of dominant negative and inactive 
Akt constructs inhibited growth factor-mediated cell survival [249,250]. However, our 
Akt transfection studies suggest that Akt activation is unable to rescue PC-12 cells from 
24h SH. In hypoxia-sensitive cells, hypoxia irreversibly arrests mRNA translation [30, 
251,252], an effect that may have influenced our transfections. This decreased rate of 
translation in hypoxic cells, may explain the lower expression levels in Akt-transfected 
hypoxic cells, compared to their normoxic counterparts. The lower expression of 
exogenous Akt was not sufficient to decrease hypoxic cell death that correlated with 
increased production of ROS (Figure 30 and data not shown). Therefore, greater 
expression of exogenous Akt and additional factors may be needed in order for cells to 
become resistant to hypoxia-induced cell death (204). Additional factors that regulate cell 
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survival may include cellular antioxidant enzymes and other kinase pathways. Indeed, 
transgenic and knockout studies in mice show that the major cellular antioxidants, 
superoxide dismutase (SOD) and glutathione peroxidase (GPX), may protect neurons in 
ischemic brain injury [235, 253-255]. By 24h, hypoxic cell death may occur due to a 
combination of energy depletion (less A TP), translation arrest, and an inability of 
irreversibly damaged oxidized antioxidant proteins to reduce ROS that damage proteins, 
DNA, and lipids. 
Hsp90 binds to phosphorylated and unphosphorylated Akt 
Akt binding to the Hsp90 complex is required for the stability and activation of 
Akt [63, 114, 115,256]. Unphosphorylated Akt may be phosphorylated by upstream 
kinase PDK1 [63] while bound to Hsp90, and phosphorylated Akt may evade 
dephosphorylation by phosphatase 2A [114] while bound to Hsp90. Indeed, ex vivo 
immunoprecipitation studies by Sata et. al. show kinase dead, wild type, and 
constitutively active Akt bind to Hsp90, demonstrating that Akt activity and 
phosphorylation are not required for Akt binding to Hsp90 [114]. Although GA induces a 
decrease in phosphorylation of Akt, few immunoprecipitation studies have determined 
which phosphorylation forms of Akt bind to Hsp90 in the presence of GA. Sata et. al. 
briefly mention that GA did not disrupt Akt binding to Hsp90 in their study [114], 
suggesting that unphosphorylated Akt can bind to Hsp90 even in the presence of GA. In 
addition, active phosphorylated Akt binds to immunoprecipitated Cdc37 in the presence 
of 17-AAG, which did not alter Akt binding to Cdc37, suggesting that phosphorylated 
Akt may also bind to Hsp90 in the presence of GA and its analogs [63]. Thus, the binding 
of GA and its analogs to Hsp90 may induce alterations in the conformation of the Akt-
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Hsp90 complex, that do not disrupt Akt binding to Hsp90, but do nonetheless decrease 
Akt phosphorylation and increase proteasomal degradation of Akt [63]. Perhaps, GA-
bound Hsp90 may shuttle phosphorylated and unphosphorylated Akt to the proteasome, 
where Akt is degraded. 
Overexpression of Cdc37 increases Akt binding to Hsp90 [63], while siRNA 
silencing of Cdc37 disrupts Hsp90 binding and decreases phosphorylation of Akt [257]. 
In addition, Cdc37 immunoprecipitation studies by Basso et. at. show phosphorylated 
Akt also binds to Cdc37 [63]. Furthermore, Akt binding to immunoprecipitated Cdc37 
was not altered by stimuli that increased (EGF; epidermal growth factor) and decreased 
(EGF depletion) Akt activity, and Cdc37 binding to Akt did not alter Akt activity [63]. 
However, this study by Basso et. al. did not immunoprecipitate Hsp90 in order to 
examine the effects of increased and decreased Akt phosphorylation on total binding of 
Cdc37 and Akt to Hsp90. Instead Akt binding to total Cdc37, some of which may not 
have been bound to Hsp90, was investigated. Therefore, in our study, Hsp90 was 
immunoprecipitated to examine whether Akt phosphorylation of Hsp90 alters total Hsp90 
binding. 
Akt phosphorylates Hsp90 
Previously, Hsp90 was shown to be a substrate of Akt in mesangial cells [140], 
and the current study demonstrates that Hsp90 is indeed phosphorylated by Akt in vitro 
and in PC-12 celllysates from normoxic and hypoxia cells. Sustained hypoxia increases 
Akt and Hsp90 phosphorylation that can be reversed by Akt 112 or PP2A treatments, 
implicating Akt in these phosphorylations. Hsp90 is also phosphorylated by other kinases 
[143] (PKA, CKII, kinase FA/GSK-3 alpha, AK), can autophosphorylate, and having 
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ATPase activity, may phosphorylate some of its substrates (histones and casein) [149]. 
Such phosphorylations and dephosphorylations of Hsp90 may regulate cellular responses 
to cytotoxic stimuli. For example, tyrosine kinase-dependent decreased phosphorylation 
of Hsp90 at residues Ser226 and Ser255 may inhibit apoptosome formation and caspase-9 
activation, and thereby contribute to the resistance of leukemic cells to Imatinib 
(Gleevec) chemotherapy [258]. 
Akt phosphorylation regulates normoxic and hypoxic Hsp90 complexes 
Since hypoxia alters Akt phosphorylation and Hsp90 binding, we examined 
whether Akt phosphorylation regulates the Hsp90 complex. Akt phosphorylation may 
playa role in hypoxia-induced alterations in Hsp90 binding, as the majority of identified 
Hsp90 binding proteins may be regulated by both hypoxia and Akt phosphorylation 
(Figures 35 and 38). Hsp90 binding proteins at RA or SH, mostly dissociated in response 
to Akti 112, suggesting that Akt phosphorylation globally regulates the association of 
proteins with Hsp90 complexes, and modulates cellular responses to hypoxia. 
Recruitment of proteins to Hsp90 complexes in response to hypoxia was altered by 
Akti 112. The aforementioned Dynein-Hsp90 complex interaction was not detected in the 
presence of Akti1l2 at 6h SH, suggesting this interaction requires Akt phosphorylation 
(Figure 35B). Disruption of Hsp90 binding by Akti 112 correlated with cell death, 
showing the importance of Akt phosphorylation to the Hsp90 complex and to cell 
survival. Akt-dependent regulation of GRIPl binding to Hsp90 without altering its total 
expression suggest that Hsp90 binding may alter the subcellular localization of GRIPl. 
GRIPl is implicated in ionotrophic glutamate receptor subunit 2 (GluR2) and GluR2-
lacking AMP A receptors transport to the plasma membrane and may critically affect 
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hypoxia-induced excitotoxicity [259-266]. Thus, regulation of Hsp90-GRIPI binding 
may provide an additional therapeutic target in neurological diseases or traumatic CNS 
disorders that involve excitotoxicity. The GRIPl binding protein Epherin B Receptor 
(EphBR) was also identified in an Hsp90 immunoprecipitate and not in the isotype 
control immunoprecipitate, suggesting that the GRIPI expressed in our cells may indeed 
bind Hsp90 rather than be a false positive hit [267]. Furthermore, identification of 
additional GRIPI binding proteins were identified, including EphB6R-binding Afadin 
(AF-6) and the kinesin-binding GAB A receptor interacting fragment 1 (GRIFl) strongly 
suggest a role for Hsp90 in protein shuttling (Figure 39) [268-270]. However, while this 
may be due to the lack of a suitable antibody for immunoprecipitation, immunoblots of 
Hsp90 immunoprecipitates and GRIPI immunoprecipitates failed to confirm GRIPl 
binding to Hsp90 complexes. In addition, the GRIPI binding protein GRASP} was 
identified in the isotype control immunoprecipitate [271]. However, GRIPI may 
nonetheless interact with Hsp90, and this putative interaction may be regulated by Akt. 
Indeed, Scansite revealed five putative Akt phosphorylation sites on rat GRIPl isoform 
c4 - 7 [162, 163]. In summary, Akt phosphorylation regulates cellular responses to 
hypoxia by regulating the protein interactions of the Hsp90 complex, although this study 
cannot confirm that Akt phosphorylation plays a role in cellular survival to hypoxia. 
Conclusion 
In conclusion, our study demonstrates that Hsp90 complexes regulate the survival 
of PC-12 cells by binding to Akt and Raf-l. However, this study did not allow us to 
dissociate entirely between the two main effects of GA, dissociation of the Hsp90 




GRIP1 binding proteins 
may bind Hsp90 complexes 
RA+ DMSO 
GRIP-1 binding proteins: 
EphrinB6 receptor precursor 
1H:atenin 
Binding proteins of 
GRIP-1 binding proteins: 
Cadherin-23 precursor (l).catenin) 
Afadin (EphB6R) 
SH + DMSO 
Binding proteins of 
GRIP-1 binding proteins: 
Afadin (EphB6R) 
GAB A receptor IF-1 (kinesin KIF5A-C) 
RA + Akti1/2 
Binding proteins of 
GRIP-1 binding proteins: 
Cadherin-23 precursor (l).catenin) 
SH + Akti1/2 
.. 
I GRIP-1 I 
.. 
I GRIP-1 I 
Figure 39. GRW 1 binding proteins and their other binding proteins were identified by 
LC-MS-MS in Hsp90 immunoprecipitates. The binding of Hsp90 complexes to these 
proteins may be regulated by hypoxia and or by Akt phosphorylation. 
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severe oxidative stress such as MEN-induced injury. However, Hsp90 binding may 
protect against physiological oxidative stress. 
In response to SH, Akt is phosphorylated and phosphorylates Hsp90. Although 
Akt phosphorylation of Hsp90 and Hsp90 binding concomitantly increase by 6h SH and 
correlate with cellular survival, this study cannot confirm that Akt and Hsp90 playa role 
in the survival response to hypoxia. Instead, this study shows that Hsp90 binding and 
basal phosphorylation of Akt play general roles in cellular survival. 
Our findings suggest that GA may target normoxic and hypoxic cancer cells that 
express higher levels of Hsp90 and Hsp90-binding proteins. A deeper understanding of 
the chaperone functions of Hsp90 and of the mechanisms of cytotoxicity of the 
benzoquinone ansamycin Hsp90 inhibitors may lead to the development of novel 
therapies for the treatment of cancers and neurological disorders. 
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CHAPTER VI: FUTURE STUDIES 
Overview 
Although many studies demonstrate that the chaperone Hsp90 prevents the 
proteasomal degradation of its binding proteins [63,64, 77, 88], results from Specific 
Aim 1 show that disrupting Hsp90 binding with GA targets Hsp90-binding proteins to 
non-proteosomal and non-lysosomal degradation. Hsp90 has been shown to interact with 
proteins of the calpain and caspase protein degradation pathways, and so future studies 
will focus on identifying the mechanism of GA-induced degradation of Hsp90-binding 
proteins and on the role of Hsp90 in preventing binding protein degradation by these 
alternative pathways [194, 200]. 
Specific Aim 1 
Methods from Specific Aim 1 as well as inhibitors of these alternative protein 
degradation pathways will be used to examine Hsp90 regulation of calpain-dependent 
and caspase-dependent protein degradation pathways. The effects of the Hsp90 inhibitor 
GA on the activity of calpain [272] will be measured by a fluorescent calpain assay that 
detects substrate degradation (uc-Leu-Leu-Val-Tyr-AMC is a substrate; Calbiochem) 
[272]. In addition, caspase activation may be assessed by immunoblotting lysates for pro-
caspases and intermediate caspases, using specific antibodies that have detected GA-
induced caspase activity in other cell lines [273]. Following detection of protease 
activities in PC-12 cells, pharmacological studies using specific inhibitors and activators 
of calpain and caspases will determine the role of these proteases in the GA-induced 
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degradation of dissociated Hsp90-binding proteins. Cal pain may be activated by treating 
cells with calcium and may be inhibited by calpeptin, PD 150606, and EST, inhibitors 
used previously to study Hsp90 function [205] (Calbiochem). In addition, the caspase 
inhibitor Z-V AD-FMK [205] (Calbiochem) may be used to evaluate the role of caspases 
in GA-induced protein degradation. The effects of these protease activators and inhibitors 
on the GA-induced degradation of Hsp90-binding proteins will be determin(,':d by 
immunoblotting for Hsp90 complex proteins. 
Specific Aim 2 
Specific Aim 2 of this study showed that basal Akt phosphorylation positively 
regulates survival by modulating the protein interactions of the Hsp90 complex. Future 
studies will determine whether this Akt phosphorylation regulates cell survival by 
altering Hsp90-dependent shuttling of Hsp90-binding proteins to subcellular sites of 
degradation. 
Future methods 
In order to study Hsp90 shuttling of its binding proteins, methods from Specific 
Aims 1 and 2 will be used in combination with co-immunostaining, confocal microscopy, 
and subcellular fractionation (Figure 40). The effects of 6h SH on co-localization of 
Hsp90-binding proteins with Hsp90, in the presence and absence of NAC and GA will 
first be examined to determine whether GA alters localization of binding proteins during 
RA and SH (Figure 40). After using GA to confirm that Hsp90 function modulates 
binding protein subcellular localization, the role of Akt phosphorylation of Hsp90 in 
Hsp90-dependent shuttling will be studied using the Akt phosphorylation inhibitor, 
Akti1l2. Use of specific antibody and dye markers for plasma membrane, cytosol, 
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Figure 40. For future studies, methods from Specific Aims 1 and 2 in combination with 
immunocytochemistry, confocal microscopy, and subcellular fractionation will be used. 
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perinuclear regions, nucleus, and mitochondria will allow evaluation of the purity of 
subcellular fractions and assist in determining the subcellular localization of Hsp90 
complex proteins. Subcellular fractions of greatest interest include cytosolic and plasma 
membrane extracts, since Hsp90 and Akt are primarily cytosolic and Akt is activated at 
the plasma membranes. Furthermore, LC-MS-MS analysis of normoxic and hypoxic 
Hsp90 complexes identified many cytosolic Hsp90-binding proteins, including Dynein, 
PFK 1, and PFK2, as well as additional Hsp90-binding proteins known to regulate 
exocytosis that may localize to the plasma membrane. In addition, the role of Dynein in 
the nuclear localization of Hsp90-binding proteins will be assessed and the effect of 
dimpting Hsp90-Dynein binding on hypoxia-induced transcriptional responses will be 
evaluated. Cells exposed to 6h of RA or SH in the presence or absence of NAC and GA 
or of Akti 112 will be fractionated and fractions immunoblotted for Hsp90 and 
Hsp90-binding proteins. Future studies are expected to show that both GA and Akti 112 
inhibit hypoxia-induced increases in Hsp90 co-localization with Akt and other binding 
proteins. In conclusion, future studies will focus on determining the role of Akt 
phosphorylation in Hsp90-dependent shuttling of proteins, that play roles in cellular 
survival. 
Conclusion 
These future studies will provide novel mechanistic insight on the role of 
Hsp90-Akt interactions in the pathophysiology of diseases. By regulating survival, the 
Hsp90-Akt complex may influence the progression of a variety of cancers and 
neurological diseases that are frequently associated with hypoxia. 
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AF-6 = Afadin; binds to EphB6R 
AGC family kinases = a family of kinases that includes cyclic nucleotide regulated 
protein kinases (PKA and PKG), diacylglycerol-activated/phospholipid-dependent PKC, 
and kinases related to PKA and PKC (RAC and Akt) 
AK = Autophosphorylation-dependent protein kinase 
Akt = Protein kinase B 
Akti 112 = Akt Inhibitor VIII 
Aktide-2T = peptide substrate for Akt; 
Ala-Arg-Lys-Arg-Glu-Arg-Thr-Tyr-Ser-Phe-Gly-His-His-Ala 
ANOV A = Analysis of variance 
BAF = Bafilomycin Al 
BCEC = bovine coronary endothelial cells 
CA = constitutively active 
CHO = chinese hamster ovary 
CKII = casein kinase II 
CMA = chaperone mediated autophagy 
DAPI = 4', 6-diamidino-2-phenylindole dihydrochloride 
DCF = 2',7'-dichlorofluorescin 
DMSO = dimethyl sulfoxide 
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1 ~D RP LC-MS~MS = 1 ~dimensional reverse phase liquid chromatography mass 
spectrometry~mass spectrometry 
DTT = Dithiothreitol 
Dynein = cytosolic dynein heavy chain 
EDT A = ethylenediaminetetraacetic acid 
EGF = epidermal growth factor 
EGFR = epidermal growth factor receptor 
EphB6R = Ephrin type~B receptor 6 
ErbB2 = v~erb~b2 erythroblastic leukemia viral oncogene homolog 2 
Fru~2,6~P2 = fructose~2,6~bisphosphate 
G, GA = Geldanamycin 
GABA receptor = gamma~aminobutyric acid receptor 
GluR2 = ionotrophic AMPA glutamate receptor subunit 2 
GPX = glutathione peroxidase 
GRASP1 = GRIPl~associated protein 1 
GRIFl = kinesin~binding GABA receptor interacting fragment 1 
GRIPl = glutamate receptor interacting protein 
GSK3~a = Glycogen synthase kinase 3a = Factor A is phosphorylated by Akt 
HEK293 = human embryonic kidney cells 
Hif~la = hypoxia~inducible factor la 
HlR = hypoxiaJreoxygenation 
HRP = horseradish peroxidase 
HSP = heat shock protein 
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Hsp90 = heat shock protein 90 
IPG = immobilized pH gradient 
IEF = isoelectric focusing 
IKK = IKE kinase 
KREBS+ = Krebs-Ringer phosphate buffer, pH 7.2 
M, MEN = menadione 
MALDI-ToF = Matrix assisted laser desorptionlionization time-of-flight mass 
spectrometry 
MCF-7 = human breast adenocarcinoma cell line from a 69 year old Caucasian woman 
MG-132 = Z-Leu-Leu-Leu-aldehyde (Z-LLL-CHO) 
MTT = 3-(4, 5-dimethyldiazol-2yl)-2, 5, -diphenyltetrazolium bromide 
NAC = N-acetyl cysteine 
NADPH = Reduced form of nicotinamide adenine dinucleotide phosphate 
NF-KE = nuclear factor kappa B subunit 
NGF = nerve growth factor 
NIH3T3 = mouse embryonic fibroblast cell line from an NIH Swiss mouse embryo. 
NIK = NF-KE-inducing kinase; Mitogen-activated protein kinase kinase kinase 14 
NOS 1 = neuronal nitric oxide synthase 1 
NOS3 = endothelial nitric oxide synthase 3 
NP-40 = nonyl phenoxylpolyethoxylethanol (Tergitol-type NP-40) 
P AEC = pulmonary artery endothelial cells 
PAGE = polyacrylamide gel electrophoresis 
PBS = phosphate-buffered saline 
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PFK 1 = phosphofructokinase 1 
PFK2 = phosphofructokinase 2 
PI3K = phosphatidylinositol 3-kinase 
PKA = cAMP-dependent protein kinase 
PKC = protein kinase C 
PMSF = phenylmethylsulphonyl fluoride 
PP2A = protein phosphatase 2A 
PTEN = phosphatase and tensin homolog deleted on chromosome 10 
PTPase = protein tyrosine phosphatase 
Rab2 = Ras-related protein 
Rab3-1M 1 = Rab3 interacting molecule 1 
Rab3-IM2 = Rab3-interacting molecule 2 
RPMI1640 = serum-free medium with L-glutamine used for the culture of PC-12 cells 
and developed by Moore et. al. at Roswell Park Memorial Institute 
SDS = sodium dodecyl sulfate 
SH = 0.1 % O2 sustained hypoxia, 5% CO2, and balanced N2 
siRNA = small interfering RNA 
SGK = serum- and glucocorticoid-regulated kinase 
SKBr3 = human breast adenocarcinoma cell line from a 43 year old Caucasian woman 
SNAP25 = 25 kDa synaptosomal-associated protein 
SNIP = SNAP25-interacting protein 
SOD-l = superoxide dismutase 1 
TBST = tris-buffered saline with Tween-20 
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TEABC = triethyl ammonium bicarbonate 
TERT = telomerase reverse transcriptase 
WT = wild type 
Tris = tris(hydroxymethyl)aminomethane ((HOCH2)3CNH2) 
VEGF = vascular endothelial growth factor 
V ~dep L~type Ca +2 channel = voltage~dependent L-type calcium channel 
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